

- Ben-Yehuda O (see Mitchell et al). 2002;144:e9  
Berdan L (see Mukherjee et al). 2002;144:995-1002  
Berkowitz SD (see Gilchrist et al). 2002;144:73-80  
Berkowitz SD (see Madan et al). 2002;144:151-8  
Berni G (see Conti et al). 2002;144:630-5  
BET study group (see Elbaz et al). 2002;144:e7  
Betriu A (see Anguera et al). 2002;144:811-17  
Bhat A, Harikrishnan S, Tharakan JM, Titus T, Ajith kumar VK, Sivasankaran S, Bimal F, Krishnamoorthy KM. Comparison of percutaneous transmyocardial resection with Inoue balloon technique and metallic commissurotomy: immediate and short-term follow-up results of a randomized study. 2002;144:1074-80  
Bhuripanyo K (see Krittaphong et al). 2002;144:e15  
Bianco-Battles D (see Di Carli et al). 2002;144:711-18  
Biffi M (see Boriani et al). 2002;144:851-7  
Bigonzi F (see Cohen et al). 2002;144:470-7  
Bimal F (see Bhat et al). 2002;144:1074-80  
Blue JW (see Tardif et al). 2002;144:589-96 (Trial design)  
Blumenthal RS (see Allen et al). 2002;144:678-86  
Boersma E (see Schinkel et al). 2002;144:865-9  
Boivin J-M (see Zannad et al). 2002;144:508-15  
Bolognese L (see Antoniucci et al). 2002;144:315-22  
Boman K (see Wachtell et al). 2002;144:1057-64  
Bonneau HN (see Okura et al). 2002;144:323-8  
Boriani G, Biffi M, Camanini C, Sammali A, Bacchi L, Accorti P, Luceri R, Zannoli R, Branzi A. Transvenous internal cardioversion for atrial fibrillation: a randomized comparison between catheters with different coil length. 2002;144:851-7  
Borzak S (see Cohen et al). 2002;144:470-7  
Borzak S (see Klingler et al). 2002;144:51-9  
Borzak S (see McCullough et al). 2002;144:226-32  
Bosch X (see Anguera et al). 2002;144:811-17  
Boucek MM (see Shaddy et al). 2002;144:383-9 (Trial design)  
Boulet V (see Elbaz et al). 2002;144:e7  
Bourassa MG (see Holubkov et al). 2002;144:826-33  
Bousman S (see Hershberger et al). 2002;144:1081-6  
Branzi A (see Boriani et al). 2002;144:851-7  
Braunwald E (see Angeja et al). 2002;144:649-56  
Braunwald E (see Cooper et al). 2002;144:790-5  
Brodsky MA, Mitchell LB, Halperin BD, Raitt MH, Hallstrom AP, AVID Investigators. Prognostic value of baseline electrophysiology studies in patients with sustained ventricular tachyarrhythmia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. 2002;144:478-84  
Brott BC (see Hillegass et al). 2002;144:501-7  
Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, Miller E, Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. 2002;144:1036-43  
Bruch C, Herrmann B, Schermermund A, Bartel T, Mann K, Erbel R. Impact of disease activity on left ventricular performance in patients with acromegaly. 2002;144:538-43  
Bruntz J-F (see Zannad et al). 2002;144:508-15  
Buonamici P (see Antoniucci et al). 2002;144:315-22  
Burch GH (see Shaddy et al). 2002;144:383-9 (Trial design)  
Burger AJ, Horton DP, Lejemtel T, Ghali JK, Torre G, Dennish G, Koren M, Dinerman J, Silver M, Cheng ML, Elkayam U. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. 2002;144:1102-8  
Burr J (see Shaddy et al). 2002;144:383-9 (Trial design)
- C**
- Caballero E (see de Lezo et al). 2002;144:877-80  
Cadeddu C (see Colonna et al). 2002;144:796-803  
Cain P (see Najos-Valencia et al). 2002;144:516-23  
Calhoun D (see White et al). 2002;144:657-65  
Califf RM (see Anderson et al). 2002;144:81-8, 769-81 (Meetings)  
Califf RM (see Gilchrist et al). 2002;144:73-80  
Califf RM (see Hillegass et al). 2002;144:501-7  
Califf RM (see Mukherjee et al). 2002;144:995-1002  
Califf RM (see Newby et al). 2002;144:957-80 (Meetings)  
Camanini C (see Boriani et al). 2002;144:851-7  
Camargo CA Jr (see Walsh et al). 2002;144:1003-11  
Campana C (see Lanzarini et al). 2002;144:1087-94  
Campisi R (see Di Carli et al). 2002;144:711-18  
Cannon CP (see Angeja et al). 2002;144:649-56  
Cantor WJ, Miller JM, Hellkamp AS, Kramer JM, Peterson ED, Hasselblad V, Zidar JP, Newby LK, Ohman EM. Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women. 2002;144:297-302  
Carballo J (see Figueras et al). 2002;144:251-8  
Carlier SG (see Thury et al). 2002;144:136-43  
Carlquist JF (see Horne et al). 2002;144:491-500  
Carrie D (see Elbaz et al). 2002;144:e7  
Carson PE (see Neuberg et al). 2002;144:31-8  
Case C (see Najos-Valencia et al). 2002;144:516-23  
Cattellier D (see Folsom et al). 2002;144:233-8  
Celentano DD (see Meng et al). 2002;144:642-8  
Cerasano G (see Antoniucci et al). 2002;144:315-22  
Ceska R (see Melenovsky et al). 2002;144:e6  
Cetner L (see Klingler et al). 2002;144:51-9  
Chaitiraphan S (see Krittaphong et al). 2002;144:e15  
Chang C-T (see Mitchell et al). 2002;144:e9  
Chang W-C (see Wong et al). 2002;144:987-94  
Chapman GD (see Hillegass et al). 2002;144:501-7  
Chau AK-t (see Cheung et al). 2002;144:159-64  
Chauhan VS, Krahn AD, Walker BD, Klein GJ, Skanes AC, Yee R. Sex differences in QTc interval and QT dispersion: dynamics during exercise and recovery in healthy subjects. 2002;144:858-64  
Chen L (see Colonna et al). 2002;144:796-803  
Chen S (see Meng et al). 2002;144:642-8  
Chen Y-X (see Glover et al). 2002;144:702-9  
Cheng ML (see Burger et al). 2002;144:1102-8  
Cheng VY-w (see Cheung et al). 2002;144:159-64  
Cherng W-J (see Wang et al). 2002;144:275-81  
Cheung Y-f, Cheng VY-w, Yung T-c, Chau AK-t. Cardiac rhythm and symptomatic arrhythmia in right atrial isomerism. 2002;144:159-64  
Chiang F-T (see Lai et al). 2002;144:485-90  
Chitra R (see Brown et al). 2002;144:1036-43  
Chiu A (see Wiecek et al). 2002;144:834-9  
Chowta N (see Prabha et al). 2002;144:e10 (Letter)  
Christenson R (see Wiecek et al). 2002;144:834-9  
Christie DJ (see Madan et al). 2002;144:151-8  
CIDS Investigators (see Irvine et al). 2002;144:282-9  
Citron B (see Elbaz et al). 2002;144:e7  
Clark C (see Alexander et al). 2002;144:431-9  
Coates K (see Hershberger et al). 2002;144:1081-6  
Coats AJ (see Shamim et al). 2002;144:740-4  
Coats AJ (see Faris et al). 2002;144:343-50  
Coats AJ (see Florea et al). 2002;144:45-50  
Cody RJ (see Koelling et al). 2002;144:524-9  
Cohen HA (see Holubkov et al). 2002;144:826-33  
Cohen M, Theroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F, ACUTE II Investigators. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. 2002;144:470-7  
Cohen M (see Kereiakes et al). 2002;144:615-24  
Colin L (see Marquez et al). 2002;144:187-97 (Curriculum cardiol.)  
Colombo F (see Avanzini et al). 2002;144:726-32  
Colonna P, Cadeddu C, Montisci R, Ruscazio M, Selem AH, Chen L, Onnis E, Meloni L, Illiceto S. Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina. 2002;144:796-803

- Connolly SJ (see Irvine et al). 2002;144:282-9  
 Connuck D (see Mehta et al). 2002;144:1109-15  
 Conti A, Paladini B, Toccafondi S, Magazzini S, Olivetto I, Galassi F, Pironi C, Santoro G, Antonucci D, Berni G. Effectiveness of a multidisciplinary chest pain unit for the assessment of coronary syndromes and risk stratification in the Florence area. 2002;144:630-5  
 Cooper HA, de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Gibson CM, Antman EM, Braunwald E. Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. 2002;144:790-5  
 Corsetti A (see Avanzini et al). 2002;144:726-32  
 Cortadellas J (see Figueras et al). 2002;144:251-8  
 Craft LL (see Wagoner et al). 2002;144:840-6  
 Crijns HJGM (see van den Brink et al). 2002;144:219-25 (Trial design)  
 Cropp AB (see Neuberger et al). 2002;144:31-8  
 Čulić V, Eterović D, Mirić D, Silić N. Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors. 2002;144:1012-17  
 Cupples LA (see Walsh et al). 2002;144:733-9  
 Curtin EL (see Shaddy et al). 2002;144:383-9 (Trial design)  
 Curtis AB. Demise of the routine electrophysiologic study for survivors of life-threatening ventricular arrhythmias. 2002;144:380-2 (Editorial)  
**D**  
 Dahlöf B (see Wachtell et al). 2002;144:1057-64  
 Daly PA (see Austin et al). 2002;144:290-6  
 Darius H (see Kereiakes et al). 2002;144:615-24  
 Dauterman KW (see Gibson et al). 2002;144:130-5  
 de Groot AC (see de Milliano et al). 2002;144:e3  
 de Lemos J (see Angeja et al). 2002;144:649-56  
 de Lemos JA (see Cooper et al). 2002;144:790-5  
 de Lezo JS, Medina A, Romero M, Pan M, Segura J, Caballero E, Pavlovic D, Ortega JR, Franco M, Delgado A, Ojeda S, Mesa D, Lafuente M. Effectiveness of percutaneous device occlusion for atrial septal defect in adult patients with pulmonary hypertension. 2002;144:877-80  
 de Milliano PAR, de Groot AC, Tijssen JGP, van Eck-Smit BLF, van Zwieten PA, Lie KI. Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure. 2002;144:e3  
 de Roos A (see Paelinck et al). 2002;144:198-205 (Progress cardiol.)  
 Dean DM (see Lee et al). 2002;144:60-7  
 DEBATE Investigators (see Thury et al). 2002;144:136-43  
 Deedwania PC (see Matalaka et al). 2002;144:674-7  
 Delgado A (see de Lezo et al). 2002;144:877-80  
 Dellborg M (see Herlitz et al). 2002;144:89-94  
 DeLong JF (see Ahmed et al). 2002;144:365-72  
 Dennish G (see Burger et al). 2002;144:1102-8  
 DeRegis JR (see Sung et al). 2002;144:39-44  
 Detre KM (see Holubkov et al). 2002;144:826-33  
 Devereux RB (see Olsen et al). 2002;144:530-7  
 Devereux RB (see Wachtell et al). 2002;144:1057-64  
 Di Carli MF, Alfonso L, Campisi R, Ramappa P, Bianco-Battles D, Grunberger G, Scheibel HR. Coronary vascular dysfunction in premenopausal women with diabetes mellitus. 2002;144:711-18  
 Dietz R (see Friedrich et al). 2002;144:329-34  
 Dige-Petersen H (see Olsen et al). 2002;144:530-7  
 Dimsdale JE (see von Känel et al). 2002;144:68-72  
 Dinerman J (see Burger et al). 2002;144:1102-8  
 Dodge JT Jr (see Gibson et al). 2002;144:130-5  
 Doehner W (see Florea et al). 2002;144:45-50  
 Donahue M, Kraus W, Granger C. Genetics in heart failure: practical incorporation of this new biologic dimension. 2002;144:938-40 (Editorial)

- Donahue MA (see Nguyen et al). 2002;144:549-60 (Meetings)  
 Dorian P (see Irvine et al). 2002;144:282-9  
 Dorn GW II (see Wagoner et al). 2002;144:840-6  
 Doss M, Martens S, Hemmer W. Emergency endovascular interventions for ruptured thoracic and abdominal aortic aneurysms. 2002;144:544-8  
 Dotani MI (see Gibson et al). 2002;144:130-5  
 Doucet M, Eisenberg M, Joseph L, Pilote L. Effects of hospital volume on long-term outcomes after percutaneous transluminal coronary angioplasty after acute myocardial infarction. 2002;144:144-50  
 Drouin P (see Zannad et al). 2002;144:508-15  
 Dubach P (see Myers et al). 2002;144:719-25  
 Duperval M (see Bedell et al). 2002;144:239-42  
 Duxbury AS (see Ahmed et al). 2002;144:365-72  
 Dyke C (see Mukherjee et al). 2002;144:995-1002

**E**

- Edwards C, Stewart RAH, Ramanathan K, West TM, French JK, White HD. Increased myocardial ischemia after food is not explained by endothelial dysfunction. 2002;144:e8  
 Egstrup K (see Sondergaard et al). 2002;144:108-14  
 Eguchi Y (see Inoue et al). 2002;144:e5  
 Eisenberg M (see Doucet et al). 2002;144:144-50  
 Elbaz M, El Mokhtar E, Khalifé K, Citron B, Izaaz K, Hamon M, Juliard JM, Leclercq F, Fourcade J, Lipieccki J, Sabatier R, Boulet V, Rinaldi J-P, Mourali S, Fatouch M, Asmar A, Steg PG, Puel J, Carrié D. BET study group. Is direct coronary stenting the best strategy for long-term outcome? Results of the multicentric randomized benefit evaluation of direct coronary stenting (BET) study. 2002;144:e7  
 Elhendy A (see Schinkel et al). 2002;144:865-9  
 Elkayam U (see Burger et al). 2002;144:1102-8  
 Ellenbogen K (see Lopez-Jimenez et al). 2002;144:687-92  
 EMIT Investigators (see Mitchell et al). 2002;144:e9  
 Erbel R (see Bruch et al). 2002;144:538-43  
 Erbel R (see Schmermund et al). 2002;144:212-18 (Trial design)  
 Ernst E. Chelation therapy for coronary heart disease. 2002;144:e11 (Letter reply)  
 Ernst SMPG (see Walhout et al). 2002;144:180-6  
 Espeland MA (see Kostis et al). 2002;144:625-9  
 Eterović D (see Čulić et al). 2002;144:1012-17  
 Every N, Hallstrom A, McDonald KM, Parsons L, Thom D, Weaver D, Hlatky MA. Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease. 2002;144:390-6  
 Every N (see Mathew et al). 2002;144:463-9  
 Exner DV. Quality of life in patients with life-threatening arrhythmias: does choice of therapy make a difference? 2002;144:208-11 (Editorial)

**F**

- Al Falluji N, Lawrence-Nelson J, Kostis JB, Lacy CR, Ranjan R, Wilson AC. Myocardial Infarction Data Acquisition system (MIDAS #8) Study Group. Effect of anemia on 1-year mortality in patients with acute myocardial infarction. 2002;144:636-41  
 Faris R, Coats AJS, Hencin MY. Echocardiography-derived variables predict outcome in patients with nonischemic dilated cardiomyopathy with or without a restrictive filling pattern. 2002;144:343-50  
 Fatouch M (see Elbaz et al). 2002;144:e7  
 Feihl F (see Pellaton et al). 2002;144:269-74  
 Felmeden DC, Beevers DG, Lip GYH. Tackling malignant hypertension: not so desperate now. 2002;144:e4 (Letter)  
 Ferguson JJ (see Kereiakes et al). 2002;144:615-24  
 Ferguson JJ III (see Perin et al). 2002;144:693-701  
 Ferrario G (see Avanzini et al). 2002;144:1018-25

- Figueras J, Juncal A, Carballo J, Cortadellas J, Soler JS. Nature and progression of pericardial effusion in patients with a first myocardial infarction: relationship to age and free wall rupture. 2002;144:251-8
- Filella X (see Anguera et al). 2002;144:811-17
- Fish RD (see Perin et al). 2002;144:693-701
- Fitchett D (see Goodman et al). 2002;144:243-50
- Fitzgerald PJ (see Okura et al). 2002;144:323-8
- Flather M (see Shamim et al). 2002;144:740-4
- Florez VG, Hencin MY, Rauchhaus M, Koloczek V, Sharma R, Doehner W, Poole-Wilson PA, Coats AJS, Anker SD. The cardiac component of cardiac cachexia. 2002;144:45-50
- Floriani I (see Avanzini et al). 2002;144:726-32
- Folmar S (see Kostis et al). 2002;144:625-9
- Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-Reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. 2002;144:233-8
- Fontana A (see Lanzarini et al). 2002;144:1087-94
- Fourcade J (see Elbaz et al). 2002;144:e7
- Foussas SG (see Zairis et al). 2002;144:782-9
- Fradley LG (see Mehta et al). 2002;144:1109-15
- Franchini M (see Lippi et al). 2002;144:e14 (Letter)
- Franco M (see de Lezo et al). 2002;144:877-80
- Frandsen E (see Olsen et al). 2002;144:530-7
- Franzosi MG (see Avanzini et al). 2002;144:1018-25
- Frederick P (see Mathew et al). 2002;144:463-9
- French JK (see Edwards et al). 2002;144:e8
- Frey A (see O'Connor et al). 2002;144:583-8 (Trial design)
- Frey MJ (see Cohen et al). 2002;144:470-7
- Frid DJ (see Neuberg et al). 2002;144:31-8
- Friedrich MG, Schulz-Menger J, Poetsch T, Pilz B, Uhlich F, Dietz R. Quantification of valvular aortic stenosis by magnetic resonance imaging. 2002;144:329-34
- Froelicher VF (see Morise et al). 2002;144:818-25
- Froland SS (see Gullestad et al). 2002;144:847-50
- Fujii T (see Hongo et al). 2002;144:122-9
- Fujita M (see Kinugawa et al). 2002;144:e1
- Fukui T (see Matsui et al). 2002;144:101-7
- Funder JW. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. 2002;144:S8-11

## G

- Gagnon D (see Orford et al). 2002;144:95-100
- Galassi F (see Conti et al). 2002;144:630-5
- Galatius S, Gustafsson F, Nielsen PH, Atar D, Hildebrandt PR. An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area. 2002;144:e2
- Gallup D (see Mukherjee et al). 2002;144:995-1002
- Garber AM (see Hlatky et al). 2002;144:397-403
- Garber AM (see McDonald et al). 2002;144:413-21
- Gardetto N (see Wieczorek et al). 2002;144:834-9
- Garg M (see McCullough et al). 2002;144:226-32
- Gattis WA (see O'Connor et al). 2002;144:583-8 (Trial design)
- Gaziano JM (see Orford et al). 2002;144:95-100
- Gent M (see Irvine et al). 2002;144:282-9
- Georgiadis M (see Adamopoulos et al). 2002;144:359-64
- Geppert J (see McDonald et al). 2002;144:413-21
- Gerdts E (see Wachtell et al). 2002;144:1057-64
- Gersh B (see Mathew et al). 2002;144:463-9
- Gersh BJ (see Kilborn et al). 2002;144:1095-101
- Gervais PB (see Lee et al). 2002;144:60-7
- Geshi E (see Koba et al). 2002;144:1026-35
- Ghali JK (see Burger et al). 2002;144:1102-8
- Gheorghiade M (see O'Connor et al). 2002;144:583-8 (Trial design)
- Giani P (see Avanzini et al). 2002;144:1018-25
- Gibler WB (see Anderson et al). 2002;144:81-8
- Gibler WB (see Wong et al). 2002;144:987-94

- Gibson CM, Dotani MI, Murphy SA, Marble SJ, Dauterman KW, Michaels AD, Dodge JT Jr, RESTORE Investigators. Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. 2002;144:130-5
- Gibson CM (see Angeja et al). 2002;144:649-56
- Gibson CM (see Cooper et al). 2002;144:790-5
- Gibson DG (see Li et al). 2002;144:173-9
- Gibson DG (see Shamim et al). 2002;144:740-4
- Gilchrist IC, Berkowitz SD, Thompson TD, Califf RM, Granger CB. Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. 2002;144:73-80
- Gille B (see Zannad et al). 2002;144:508-15
- GISSI-3 Investigators (see Avanzini et al). 2002;144:1018-25
- Giugliano RP (see Walsh et al). 2002;144:1003-11
- Glover C, Ma X, Chen Y-X, Miller H, Veinot J, Labinaz M, O'Brien E. Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation. 2002;144:702-9
- Gnarpe J (see Wong et al). 2002;144:987-94
- Goldberg R (see Bedell et al). 2002;144:239-42
- Goldberg RJ (see Jackson et al). 2002;144:259-68
- Goldman L (see Lopez-Jimenez et al). 2002;144:687-92
- Goldstein CL, Racz M, Hannan EL. Impact of cardiac catheterization-percutaneous coronary intervention timing on in-hospital mortality. 2002;144:561-7 (Progress cardiol.)
- Goodman S (see Lee et al). 2002;144:60-7
- Goodman SG, Barr A, Langer A, Wagner GS, Fitchett D, Armstrong PW, Naylor CD. Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era. 2002;144:243-50
- Gore JM (see Jackson et al). 2002;144:259-68
- Gottdiener JS, Panza JA, St John Sutton M, Bannon P, Kushner H, Weissman NJ. Testing the test: the reliability of echocardiography in the sequential assessment of valvular regurgitation. 2002;144:115-21
- Gottlieb S (see Wieczorek et al). 2002;144:834-9
- Gotto AM Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. 2002;144:S33-42
- Gotto AM Jr, Paoletti R. New options in lipid management—can we extend the benefits of current therapy?—Introduction. 2002;144:S19-20
- Graf S (see Speidl et al). 2002;144:449-55
- Granger C (see Donahue et al). 2002;144:938-40 (Editorial)
- Granger CB (see Gilchrist et al). 2002;144:73-80
- Green-Weir R (see Klingler et al). 2002;144:51-9
- Grégoire J (see Tardif et al). 2002;144:589-96 (Trial design)
- Grentzinger A (see Zannad et al). 2002;144:508-15
- Grines C (see Kereiakes et al). 2002;144:615-24
- Grönemeyer D (see Schmermund et al). 2002;144:212-18 (Trial design)
- Grunberger G (see Di Carli et al). 2002;144:711-18
- Guevara M (see Marquez et al). 2002;144:187-97 (Curriculum cardiol.)
- Guidi G (see Lippi et al). 2002;144:e14 (Letter)
- Gullestad L, Semb AG, Holt E, Skårud R, Ueland T, Yndestad A, Froland SS, Aukrust P. Effect of thalidomide in patients with chronic heart failure. 2002;144:847-50
- Gustafsson F (see Galatius et al). 2002;144:e2

## H

- Hadjissavvas JJ (see Zairis et al). 2002;144:782-9
- Hager D (see Wieczorek et al). 2002;144:834-9
- Hallstrom A (see Every et al). 2002;144:390-6
- Hallstrom AP (see Brodsky et al). 2002;144:478-84
- Halonen P (see Tuomainen et al). 2002;144:870-6
- Halperin BD (see Brodsky et al). 2002;144:478-84
- Hammadi M (see Zannad et al). 2002;144:508-15
- Hamon M (see Elbaz et al). 2002;144:e7

- Hanada H (see Kinugawa et al). 2002;144:e1  
 Handt S (see Radke et al). 2002;144:e12 (Letter)  
 Hannan EL (see Goldstein et al). 2002;144:561-7 (Progress cardiol.)  
 Hannan M (see Walsh et al). 2002;144:733-9  
 Hanotin C (see Zannad et al). 2002;144:508-15  
 Hanrath P (see Radke et al). 2002;144:e12 (Letter)  
 Hanson EL (see Hershberger et al). 2002;144:1081-6  
 Hari Krishnan S (see Bhat et al). 2002;144:1074-80  
 Harrington RA (see Mukherjee et al). 2002;144:995-1002  
 Harris K (see Cohen et al). 2002;144:470-7  
 Harrison KW (see Kostis et al). 2002;144:625-9  
 Hasselblad V (see Cantor et al). 2002;144:297-302  
 Hassman DR (see Brown et al). 2002;144:1036-43  
 Hauser ER (see Kraus and Hauser). 2002;144:747-9 (Editorial)  
 Haviland A (see Holubkov et al). 2002;144:826-33  
 Havstad S (see Klingler et al). 2002;144:51-9  
 Hayase M (see Okura et al). 2002;144:323-8  
 Hayashi T (see Inoue et al). 2002;144:e5  
 Hayashida N (see Matsui et al). 2002;144:101-7  
 Hees PS (see Sung et al). 2002;144:39-44  
 Heidenreich PA, Keffe B, McDonald KM, Hlatky MA. Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. 2002;144:422-30  
 Heidenreich PA. The search for myocardial viability: do Q waves help? 2002;144:745-6 (Editorial)  
 Heidenreich PA (see Owens et al). 2002;144:440-8  
 Heinonen T (see Tardif et al). 2002;144:589-96 (Trial design)  
 Heinz Nixdorf Recall Study Investigative Group (see Schmermund et al). 2002;144:212-18 (Trial design)  
 Hellkamp AS (see Cantor et al). 2002;144:297-302  
 Hemmer W (see Doss et al). 2002;144:544-8  
 Hendrican K (see McKelvie et al). 2002;144:23-30  
 Hencin M (see Shamim et al). 2002;144:740-4  
 Hencin MY (see Faris et al). 2002;144:343-50  
 Hencin MY (see Florea et al). 2002;144:35-50  
 Hencin MY (see Li et al). 2002;144:173-9  
 Herlitz J, Dellborg M, Karlsson BW, Karlsson T. Prognosis after acute myocardial infarction continues to improve in the reperfusion era in the community of Göteborg. 2002;144:89-94  
 Hermann KL (see Olsen et al). 2002;144:530-7  
 Hermosillo AG (see Marquez et al). 2002;144:187-97 (Curriculum cardi.)  
 Herrmann B (see Bruch et al). 2002;144:538-43  
 Hershberger RE, Hanson EL, Jakobs PM, Keegan H, Coates K, Bousman S, Litt M. A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation. 2002;144:1081-6  
 Hildebrandt PR (see Galatius et al). 2002;144:e2  
 Hillegass WB, Brott BC, Chapman GD, Phillips HR, Stack RS, Tch-  
 eng JE, Califf RM. Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. 2002;144:501-7  
 Hira K (see Matsui et al). 2002;144:101-7  
 Hirano T (see Koba et al). 2002;144:1026-35  
 Hirche H (see Schmermund et al). 2002;144:212-18 (Trial design)  
 Hlatky MA, Saynina O, McDonald KM, Garber AM, McClellan MB. Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995. 2002;144:397-403  
 Hlatky MA (see Alexander et al). 2002;144:431-9  
 Hlatky MA (see Every et al). 2002;144:390-6  
 Hlatky MA (see Heidenreich et al). 2002;144:422-30  
 Hlatky MA (see Hsu et al). 2002;144:404-12  
 Hlatky MA (see McDonald et al). 2002;144:413-21  
 Hlatky MA (see Owens et al). 2002;144:440-8  
 Holt E (see Gullestad et al). 2002;144:847-50  
 Holubkov R, Laskey WK, Haviland A, Slater JC, Bourassa MG, Vlachos HA, Cohen HA, Williams DO, Kelsey SF, Detre KM, Registry Investigators. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. 2002;144:826-33  
 Hongo M, Urushibata K, Kai R, Takahashi W, Koizumi T, Uchikawa S, Imamura H, Kinoshita O, Owa M, Fujii T. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. 2002;144:122-9  
 Honig A (see van den Brink et al). 2002;144:219-25 (Trial design)  
 Hooper WC (see Kostis et al). 2002;144:625-9  
 Horne BD, Muhlestein JB, Strobel GG, Carlquist JF, Bair TL, Anderson JL, Intermountain Heart Collaborative (IHC) Study Group. Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention. 2002;144:491-500  
 Hornykewycz S (see Speidl et al). 2002;144:449-55  
 Horton DP (see Burger et al). 2002;144:1102-8  
 Hsu DT (see Shaddy et al). 2002;144:383-9 (Trial design)  
 Hsu J, Uratsu C, Truman A, Quensenberry C, McDonald KM, Hlatky MA, Selby J. Life after a ventricular arrhythmia. 2002;144:404-12  
 Hsu K-L (see Lai et al). 2002;144:485-90  
 Huang SKS (see Lai et al). 2002;144:485-90  
 Huang T-Y (see Akutsu et al). 2002;144:335-42  
 Huber K (see Speidl et al). 2002;144:449-55  
 Hudson MP (see McCullough et al). 2002;144:226-32  
 Humen D (see McKelvie et al). 2002;144:23-30  
 Hung M-J (see Wang et al). 2002;144:275-81  
 Hutchinson H (see Brown et al). 2002;144:1036-43  
 Hutter PA (see Walhout et al). 2002;144:180-6  
 Hwang JJ (see Lai et al). 2002;144:485-90
- I
- Ibsen H (see Olsen et al). 2002;144:530-7  
 Igau B (see Zannad et al). 2002;144:508-15  
 Illiceto S (see Colonna et al). 2002;144:796-803  
 Imamura H (see Hongo et al). 2002;144:122-9  
 Imus J (see Tardif et al). 2002;144:589-96 (Trial design)  
 Inoue T, Yaguchi I, Takayanagi K, Hayashi T, Morooka S, Eguchi Y. A new thrombolytic agent, monteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: initial results of the Combining Monteplase with Angioplasty (COMA) trial. 2002;144:e5  
 Inoue T (see Kamishirado et al). 2002;144:303-8  
 Intermountain Heart Collaborative (IHC) Study Group (see Horne et al). 2002;144:491-500  
 Irvine J, Dorian P, Baker B, O'Brien BJ, Roberts R, Gent M, Newman D, Connolly SJ, CIDS Investigators. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). 2002;144:282-9  
 Istad H (see Olsson et al). 2002;144:1044-51  
 Istvan ES. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. 2002;144:S27-32  
 Iturralde P (see Márquez et al). 2002;144:187-97 (Curriculum cardi.)  
 Izaaz K (see Elbaz et al). 2002;144:e7
- J
- Jackson EA, Sivasubramanian R, Spencer FA, Yarzebski J, Lessard D, Gore JM, Goldberg RJ. Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): a population-based perspective. 2002;144:259-68  
 Jaffe AS (see Apple et al). 2002;144:981-6 (Meetings)  
 Jakobs PM (see Hershberger et al). 2002;144:1081-6  
 Jernberg T, Lindahl B. A combination of troponin T and 12-lead electrocardiography: a valuable tool for early prediction of long-term mortality in patients with chest pain without ST-segment elevation. 2002;144:804-10  
 Jöckel K-H (see Schmermund et al). 2002;144:212-18 (Trial design)  
 Johnson KC (see Kostis et al). 2002;144:625-9  
 Jollis JG (see Sachdev et al). 2002;144:1065-73  
 Joseph L (see Doucet et al). 2002;144:144-50



- Jukema JW (see Agema et al). 2002;144:760-8 (Progress cardiol.)  
Juliard JM (see Elbaz et al). 2002;144:e7  
Juncal A (see Figueras et al). 2002;144:251-8  
Juncja HS (see Folsom et al). 2002;144:233-8

## K

- Kai R (see Hongo et al). 2002;144:122-9  
Kaiser A (see Radke et al). 2002;144:e12 (Letter)  
Kamishirado H, Inoue T, Mizoguchi K, Uchida T, Nakata T, Sakuma M, Takayanagi K, Morooka S. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. 2002;144:303-8  
Kandzari DE (see Nguyen et al). 2002;144:549-60 (Meetings)  
Kangkagate C (see Krittayaphong et al). 2002;144:e15  
Karas RH (see Kuvin et al). 2002;144:165-72  
Karatzas D (see Adamopoulos et al). 2002;144:359-64  
Karavolias G (see Adamopoulos et al). 2002;144:359-64  
Karlson BW (see Herlitz et al). 2002;144:89-94  
Karlsson T (see Herlitz et al). 2002;144:89-94  
Karsch KR (see Kereiakes et al). 2002;144:615-24  
Katagiri T (see Akutsu et al). 2002;144:335-42  
Katagiri T (see Koba et al). 2002;144:1026-35  
Kaufman ES (see Mehta et al). 2002;144:1109-15  
Kaul P (see Nguyen et al). 2002;144:549-60 (Meetings)  
Keefe B (see Heidenreich et al). 2002;144:422-30  
Keegan H (see Hersherberger et al). 2002;144:1081-6  
Kelly K (see Allen et al). 2002;144:678-86  
Kelsey SF (see Holubkov et al). 2002;144:826-33  
Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch KR, Kleiman NS, Moliterno DJ, Steg P-G, Teirstein P, Van de Werf F, Wallentin L. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. 2002;144:615-24  
Khalifé K (see Elbaz et al). 2002;144:e7  
Khan IA. Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter. 2002;144:11-22 (Curriculum cardiol.). Correction 2002;144:232  
Al-Khatib SM (see Anderson et al). 2002;144:769-81 (Meetings)  
Kiel DP (see Walsh et al). 2002;144:733-9  
Kilborn MJ, Rathore SS, Gersh BJ, Oetgen WJ, Solomon AJ. Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation. 2002;144:1095-101  
Kinoshita O (see Hongo et al). 2002;144:122-9  
Kinugawa T, Fujita M, Lee J-D, Nakajima H, Hanada H, Miyamoto S. Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris. 2002;144:e1  
Kirchner HL (see Mehta et al). 2002;144:1109-15  
Kleiman NS (see Kereiakes et al). 2002;144:615-24  
Klein GJ (see Chauhan et al). 2002;144:858-64  
Klein M (see Myers et al). 2002;144:719-25  
Klersy C (see Lanzarini et al). 2002;144:1087-94  
Klingler D, Green-Weir R, Nerenz D, Havstad S, Rosman HS, Cetner L, Shah S, Wimbush F, Borzak S. Perceptions of chest pain differ by race. 2002;144:51-9  
Koba S, Hirano T, Kondo T, Shibata M, Suzuki H, Murakami M, Geshi E, Katagiri T. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. 2002;144:1026-35  
Kobrin I (see O'Connor et al). 2002;144:583-8 (Trial design)  
Koelling TM, Aaronson KD, Cody RJ, Bach DS, Armstrong WF. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. 2002;144:524-9  
Koizumi T (see Hongo et al). 2002;144:122-9  
Kolh P (see Segers et al). 2002;144:568-76 (Progress cardiol.)  
Kolozcek V (see Florea et al). 2002;144:45-50  
Kondo T (see Koba et al). 2002;144:1026-35

- Koniavitu K (see Adamopoulos et al). 2002;144:359-64  
Koren M (see Burger et al). 2002;144:1102-8  
Kostis JB, Wilson AC, Hooper WC, Harrison KW, Philipp CS, Appel LJ, Espeland MA, Folmar S, Johnson KC, TONE Cooperative Research Group. Association of angiotensin-converting enzyme DD genotype with blood pressure sensitivity to weight loss. 2002;144:625-9  
Kostis JB (see Al Falluji et al). 2002;144:636-41  
Kozuma K (see Thury et al). 2002;144:136-43  
Krahn AD (see Chauhan et al). 2002;144:858-64  
Kramer JM (see Cantor et al). 2002;144:297-302  
Krams R (see Thury et al). 2002;144:136-43  
Kraus W (see Donahue et al). 2002;144:938-40 (Editorial)  
Kraus WE, Hauser ER. Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: identifying the guideposts for navigating the genetics landscape. 2002;144:747-9 (Editorial)  
Kremastinos DT (see Adamopoulos et al). 2002;144:359-64  
Krishnamoorthy KM (see Bhat et al). 2002;144:1074-80  
Krishnaswamy P (see Wiecek et al). 2002;144:834-9  
Krittayaphong R, Bhuripanyo K, Punlee K, Kangkagate C, Chaitiraphan S. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. 2002;144:e15  
Kromer A (see Schulz and Kromer). 2002;144:351-8  
Kronenberger S (see Radke et al). 2002;144:e12 (Letter)  
Kroupis C (see Adamopoulos et al). 2002;144:359-64  
Krucoff MW (see Anderson et al). 2002;144:81-8  
Krumholz HM (see Rathore et al). 2002;144:1052-6  
Kubli S (see Pellaton et al). 2002;144:269-74  
Kuo L-T (see Wang et al). 2002;144:275-81  
Kushner H (see Gottdiener et al). 2002;144:115-21  
Kuvin JT, Rämetsä ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. 2002;144:165-72

## L

- Labina M (see Glover et al). 2002;144:702-9  
Labovitz AJ (see Mitchell et al). 2002;144:e9  
Lacy CR (see Al Falluji et al). 2002;144:636-41  
Lafuente M (see de Lezo et al). 2002;144:877-80  
Lai H (see Meng et al). 2002;144:642-8  
Lai L-P, Su M-J, Yeh H-M, Lin J-L, Chiang F-T, Hwang J-J, Hsu K-L, Tseng C-D, Lien W-P, Tseng Y-Z, Huang SKS. Association of the human minK gene 38G allele with atrial fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation. 2002;144:485-90  
Lai S (see Meng et al). 2002;144:642-8  
L'Allier PL (see Tardif et al). 2002;144:589-96 (Trial design)  
Lamas GA (see Lopez-Jimenez et al). 2002;144:687-92  
Lamb HJ (see Paelinck et al). 2002;144:198-205 (Progress cardiol.)  
Lambert FPG (see van den Brink et al). 2002;144:219-25 (Trial design)  
Lambert J (see Tardif et al). 2002;144:589-96 (Trial design)  
Langer A (see Goodman et al). 2002;144:243-50  
Langer A (see Lee et al). 2002;144:60-7  
Langer A (see Wong et al). 2002;144:987-94  
Lanzarini L, Fontana A, Lucca E, Campana C, Klersy C. Noninvasive estimation of both systolic and diastolic pulmonary artery pressure from Doppler analysis of tricuspid regurgitant velocity spectrum in patients with chronic heart failure. 2002;144:1087-94  
LaRosa JC. What do the statins tell us? 2002;144:S21-6  
LaSalle B (see Shaddy et al). 2002;144:383-9 (Trial design)  
Laskey WK (see Holubkov et al). 2002;144:826-33  
Lauer MS. Exercise testing for assessment of autonomic function. 2002;144:580-2 (Editorial)

- Lauer MS (see Morise et al). 2002;144:818-25  
 Lauer MS (see Mukherjee et al). 2002;144:995-1002  
 Lauterbach K (see Schmermund et al). 2002;144:212-18 (Trial design)  
 Lawrence-Nelson J (see Al Falluji et al). 2002;144:636-41  
 Leclercq F (see Elbaz et al). 2002;144:e7  
 Lee DS, Goodman S, Dean DM, Lenis J, Ma P, Gervais PB, Langer A, PRIDE Investigators. Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial. 2002;144:60-7  
 Lee J-D (see Kinugawa et al). 2002;144:e1  
 LeJemtel T (see Burger et al). 2002;144:1102-8  
 Lekkerkerker JC (see Walhout et al). 2002;144:180-6  
 Lenis J (see Lee et al). 2002;144:60-7  
 Lésperance J (see Tardif et al). 2002;144:589-96 (Trial design)  
 Lessard D (see Jackson et al). 2002;144:259-68  
 Leung RCM, Armstrong PW. Reperfusion in waiting: what queue should we join? 2002;144:377-9 (Editorial)  
 Levinsky MJ, Ohman EM. Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients. 2002;144:750-2 (Editorial)  
 Levy D (see Walsh et al). 2002;144:733-9  
 Li H-L (see Akutsu et al). 2002;144:335-42  
 Li JS (see Pasquali et al). 2002;144:608-14 (Trial design)  
 Li W, Somerville J, Gibson DG, Henein MY. Effect of atrial flutter on exercise tolerance in patients with grown-up congenital heart (GUHC). 2002;144:173-9  
 Liao L (see Nguyen et al). 2002;144:549-60 (Meetings)  
 Lie KI (see de Milliano et al). 2002;144:e3  
 Lien W-P (see Lai et al). 2002;144:485-90  
 Liggett SB (see Wagoner et al). 2002;144:840-6  
 Lima JAC (see Meng et al). 2002;144:642-8  
 Lin J-L (see Lai et al). 2002;144:485-90  
 Lind L, Andrén B. Heart rate recovery after exercise is related to the insulin resistance syndrome and heart rate variability in elderly men. 2002;144:666-72  
 Lindahl B (see Jernberg and Lindahl). 2002;144:804-10  
 Lip GYH (see Felmeden et al). 2002;144:e4 (Letter)  
 Lipiecki J (see Elbaz et al). 2002;144:e7  
 Lippi G, Manzato F, Franchini M, Guidi G. Relationship between hematocrit, primary hemostasis, and cardiovascular disease in athletes. 2002;144:e14 (Letter)  
 Lis J (see Cohen et al). 2002;144:470-7  
 Litt M (see Herschberger et al). 2002;144:1081-6  
 Lloyd-Jones DM (see Walsh et al). 2002;144:1003-11  
 Lopez-Jimenez F, Goldman L, Orav EJ, Ellenbogen K, Stambler B, Marinchak R, Wilkoff BL, Mangione CM, Yoon C, Vitale K, Lamas GA. Health values before and after pacemaker implantation. 2002;144:687-92  
 Loyd R (see Mitchell et al). 2002;144:e9  
 Lucca E (see Lanzarini et al). 2002;144:1087-94  
 Luceri R (see Boriani et al). 2002;144:851-7  
 Luchinger R (see Myers et al). 2002;144:719-25  
 Lundergan CF, Reiner JS, Ross AM, PACT Investigators. How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction. 2002;144:456-62  
 Luurila O (see Olsson et al). 2002;144:1044-51
- M**
- Ma P (see Lee et al). 2002;144:60-7  
 Ma X (see Glover et al). 2002;144:702-9  
 MacAlpin RN. In search of left septal fascicular block. 2002;144:948-56 (Progress cardiol.)  
 Madan M, Berkowitz SD, Christie DJ, Smit AC, Sigmon KN, Tchong JE. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. 2002;144:151-8  
 Magazzini S (see Conti et al). 2002;144:630-5  
 Maglione T (see Avanzini et al). 2002;144:726-32  
 Mahaffey KW (see Mukherjee et al). 2002;144:995-1002  
 Mahony L (see Shaddy et al). 2002;144:383-9 (Trial design)  
 Maisel A (see Wiczczonek et al). 2002;144:834-9  
 Malik J (see Melnikov et al). 2002;144:e6  
 Malmgren J (see Mathew et al). 2002;144:463-9  
 Mangione CM (see Lopez-Jimenez et al). 2002;144:687-92  
 Manley HJ (see McCullough et al). 2002;144:226-32  
 Mann K (see Bruch et al). 2002;144:538-43  
 Mann K (see Schmermund et al). 2002;144:212-18 (Trial design)  
 Manousakis SJ (see Zairis et al). 2002;144:782-9  
 Mansoor GA (see White et al). 2002;144:657-65  
 Mänttari M (see Mukherjee et al). 2002;144:995-1002  
 Manzato F (see Lippi et al). 2002;144:e14 (Letter)  
 Marble SJ (see Angca et al). 2002;144:649-56  
 Marble SJ (see Gibson et al). 2002;144:130-5  
 Margolis S (see Allen et al). 2002;144:678-86  
 Marin JL (see Anguera et al). 2002;144:811-17  
 Marinchak R (see Lopez-Jimenez et al). 2002;144:687-92  
 Márquez MF, Colín L, Guevara M, Iturralde P, Hermosillo AG. Common electrocardiographic artifacts mimicking arrhythmias in ambulatory monitoring. 2002;144:187-97 (Curriculum cardi.)  
 Martens S (see Doss et al). 2002;144:544-8  
 Marwick TH (see Najos-Valencia et al). 2002;144:516-23  
 Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). 2002;144:674-7  
 Mathew V, Gersh B, Barron H, Every N, Tiefenbrunn A, Frederick P, Malmgren J. In-hospital outcome of acute myocardial infarction in patients with prior coronary artery bypass surgery. 2002;144:463-9  
 Matsui K, Fukui T, Hira K, Sobashima A, Okamatsu S, Hayashida N, Tanaka S, Nobuyoshi M. Impact of sex and its interaction with age on the management of and outcome for patients with acute myocardial infarction in 4 Japanese hospitals. 2002;144:101-7  
 Mayer K (see Myers et al). 2002;144:719-25  
 Maynard C (see Watanabe et al). 2002;144:309-14  
 McCabe CH (see Cooper et al). 2002;144:790-5  
 McCartney N (see McKelvie et al). 2002;144:23-30  
 McClellan MB (see Hlatky et al). 2002;144:397-403  
 McClellan MB (see McDonald et al). 2002;144:413-21  
 McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. 2002;144:226-32  
 McDonald KM, Hlatky MA, Saynina O, Geppert J, Garber AM, McClellan MB. Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995. 2002;144:413-21  
 McDonald KM (see Alexander et al). 2002;144:431-9  
 McDonald KM (see Every et al). 2002;144:390-6  
 McDonald KM (see Heidenreich et al). 2002;144:422-30  
 McDonald KM (see Hlatky et al). 2002;144:397-403  
 McDonald KM (see Hsu et al). 2002;144:404-12  
 McDonald KM (see Owens et al). 2002;144:440-8  
 McGuire N (see Wagoner et al). 2002;144:840-6  
 McKelvie RS, Teo KK, Roberts R, McCartney N, Humen D, Montague T, Hendrican K, Yusuf S. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). 2002;144:23-30  
 McKenney J (see Brown et al). 2002;144:1036-43  
 McMullan R, Moore JE, Silke B. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitors on serum C-reactive protein levels: possible implications. 2002;144:e13 (Letter)  
 Medina A (see de Lezo et al). 2002;144:877-80

- Mehta SK, Super DM, Connuck D, Kirchner HL, Salvator A, Singer L, Fradley LG, Kaufman ES. Autonomic alterations in cocaine-exposed infants. 2002;144:1109-15
- Meijboom EJ (see Walhout et al). 2002;144:180-6
- Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R, Stavek P, Ceska R. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. 2002;144:e6
- Meloni L (see Colonna et al). 2002;144:796-803
- Mendelsohn ME (see Kuvlin et al). 2002;144:165-72
- Meng Q, Lima JAC, Lai H, Vlahov D, Celentano DD, Strathdee SA, Nelson KE, Wu KC, Chen S, Tong W, Lai S. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. 2002;144:642-8
- Merkelbach-Bruse S (see Radke et al). 2002;144:e12 (Letter)
- Mesa D (see de Lezo et al). 2002;144:877-80
- Michaels AD (see Gibson et al). 2002;144:130-5
- Migliorini A (see Antoniucci et al). 2002;144:315-22
- Miller AB (see Neuberger et al). 2002;144:31-8
- Miller E (see Brown et al). 2002;144:1036-43
- Miller ER III (see Allen et al). 2002;144:678-86
- Miller JH (see Glover et al). 2002;144:702-9
- Miller JM (see Cantor et al). 2002;144:297-302
- Miller WC (see Sachdev et al). 2002;144:1065-73
- Mills PJ (see von Känel et al). 2002;144:68-72
- MIND-IT Investigators (see van den Brink et al). 2002;144:219-25 (Trial design)
- Miranda-Guardiola F (see Anguera et al). 2002;144:811-17
- Mirić D (see Čulić et al). 2002;144:1012-17
- Mitchell LB (see Brodsky et al). 2002;144:478-84
- Mitchell RG, Stoddard MF, Ben-Yehuda O, Aggarwal KB, Allenby KS, Trillo RA, Loyd R, Chang C-T, Labovitz AJ, EMIT Investigators. Esmolol in acute ischemic syndromes. 2002;144:e9
- Miyamoto S (see Kinugawa et al). 2002;144:e1
- Mizoguchi K (see Kamishirado et al). 2002;144:303-8
- Möhlenkamp S (see Schermund et al). 2002;144:212-18 (Trial design)
- El Mokhtar E (see Elbaz et al). 2002;144:e7
- Molitero DJ (see Kerciakes et al). 2002;144:615-24
- Molitero DJ (see Mukherjee et al). 2002;144:995-1002
- Møller JE (see Søndergaard et al). 2002;144:108-14
- Montague T (see McKelvie et al). 2002;144:23-30
- Montalescot G (see Kerciakes et al). 2002;144:615-24
- Montisci R (see Colonna et al). 2002;144:796-803
- Moore JE (see McMullan et al). 2002;144:e13 (Letter)
- Morimont P (see Segers et al). 2002;144:568-76 (Progress cardiol.)
- Morise AP, Lauer MS, Froelicher VF. Development and validation of a simple exercise test score for use in women with symptoms of suspected coronary artery disease. 2002;144:818-25
- Morooka S (see Inoue et al). 2002;144:e5
- Morooka S (see Kamishirado et al). 2002;144:303-8
- Morrow DA (see Cooper et al). 2002;144:790-5
- Moschi G (see Antoniucci et al). 2002;144:315-22
- Mourali S (see Elbaz et al). 2002;144:e7
- Muhlestein JB (see Horne et al). 2002;144:491-500
- Mukherjee D, Mahaffey KW, Molitero DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttari M, White HD, Califf RM, Topol EJ. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). 2002;144:995-1002
- Mukherjee D, Yadav JS. Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification. 2002;144:753-9 (Curriculum cardiol.)
- Mukherjee R (see Cohen et al). 2002;144:470-7
- Muller P (see Myers et al). 2002;144:719-25
- Munehchika H (see Akutsu et al). 2002;144:335-42

- Murakami M (see Koba et al). 2002;144:1026-35
- Murphy SA (see Angeja et al). 2002;144:649-56
- Murphy SA (see Cooper et al). 2002;144:790-5
- Murphy SA (see Gibson et al). 2002;144:130-5
- Myers J, Wagner D, Schertler T, Beer M, Luchinger R, Klein M, Rickli H, Muller P, Mayer K, Schwitzer J, Dubach P. Effects of exercise training on left ventricular volumes and function in patients with nonischemic cardiomyopathy: application of magnetic resonance myocardial tagging. 2002;144:719-25
- Myocardial Infarction Data Acquisition system (MIDAS #8) Study Group (see Al Falluji et al). 2002;144:636-41

## N

- Najos-Valencia O, Cain P, Case C, Wahi S, Marwick TH. Determinants of tissue Doppler measures of regional diastolic function during dobutamine stress echocardiography. 2002;144:516-23
- Nakajima H (see Kinugawa et al). 2002;144:e1
- Nakata T (see Kamishirado et al). 2002;144:303-8
- Naylor CD (see Goodman et al). 2002;144:243-50
- Naylor CD (see Parker et al). 2002;144:941-7 (Curriculum cardiol.)
- Nelson KE (see Meng et al). 2002;144:642-8
- Nerenz D (see Klingler et al). 2002;144:51-9
- Neuberger GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M, PRAISE Investigators. Diuretic resistance predicts mortality in patients with advanced heart failure. 2002;144:31-8
- Newby LK, Alpert JS, Ohman EM, Thygesen K, Califf RM. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. 2002;144:957-80 (Meetings)
- Newby LK (see Cantor et al). 2002;144:297-302
- Newman D (see Irvine et al). 2002;144:282-9
- Nguyen CM, Liao L, Trichon B, Saint-Jacques H, Kandzari DE, Donahue MA, Kaul P. Highlights from the American College of Cardiology Annual Scientific Sessions 2002: March 17 to 20, 2002. 2002;144:549-60 (Meetings)
- NHLBI Dynamic Registry Investigators (see Holubkov et al). 2002;144:826-33
- Nielsen PH (see Galatius et al). 2002;144:e2
- Nieminen MS (see Wachtell et al). 2002;144:1057-64
- Niessner A (see Speidl et al). 2002;144:449-55
- Nikfarjam M (see Speidl et al). 2002;144:449-55
- Nishimura H (see Akutsu et al). 2002;144:335-42
- Nobuyoshi M (see Matsui et al). 2002;144:101-7
- Nye RG (see Neuberger et al). 2002;144:31-8

## O

- O'Brien BJ (see Irvine et al). 2002;144:282-9
- O'Brien E (see Glover et al). 2002;144:702-9
- O'Connor CM, Gattis WA, Adams KF Jr, Shah MR, Kobrin I, Frey A, Gheorghiade M, RITZ-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan Study (RITZ-4). 2002;144:583-8 (Trial design)
- O'Connor CM (see Neuberger et al). 2002;144:31-8
- O'Connor CM (see Trichon and O'Connor). 2002;144:373-6 (Editorial)
- O'Connor CM (see Whellan and O'Connor). 2002;144:1-4 (Editorial)
- O'Donnell CJ (see Walsh et al). 2002;144:733-9, 1003-11
- Oetgen WJ (see Kilborn et al). 2002;144:1095-101
- Ohman EM (see Anderson et al). 2002;144:81-8
- Ohman EM (see Cantor et al). 2002;144:297-302
- Ohman EM (see Levinsky and Ohman). 2002;144:750-2 (Editorial)
- Ohman EM (see Newby et al). 2002;144:957-80 (Meetings)
- Ohman EM (see Wong et al). 2002;144:987-94
- Ojeda S (see de Lezo et al). 2002;144:877-80
- Okamatsu S (see Matsui et al). 2002;144:101-7

- Okura H, Shimodozono S, Hayase M, Bonneau HN, Yock PG, Fitzgerald PJ. Impact of deep vessel wall injury and vessel stretching on subsequent arterial remodeling after balloon angioplasty: a serial intravascular ultrasound study. 2002;144:323-8
- Olivetto I (see Conti et al). 2002;144:630-5
- Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux RB, Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. 2002;144:530-7
- Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW, Rosuvastatin Investigators Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. 2002;144:1044-51
- Olympios CD (see Zairis et al). 2002;144:782-9
- Onnis E (see Colonna et al). 2002;144:796-803
- Orav EJ (see Lopez-Jimenez et al). 2002;144:687-92
- Ordin DL (see Rathore et al). 2002;144:1052-6
- Orford JL, Sesso HD, Stedman M, Gagnon D, Vokonas P, Gaziano JM. A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the Normative Aging Study. 2002;144:95-100
- Ormel J (see van den Brink et al). 2002;144:219-25 (Trial design)
- Ortega JR (see de Lezo et al). 2002;144:877-80
- Ortlepp JR (see Radke et al). 2002;144:e12 (Letter)
- Ose L (see Olsson et al). 2002;144:1044-51
- Ouyang P (see Sung et al). 2002;144:39-44
- Owa M (see Hongo et al). 2002;144:122-9
- Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. 2002;144:440-8

## P

- Packer M (see Neuberger et al). 2002;144:31-8
- PACT Investigators (see Lundergan et al). 2002;144:456-62
- Paelinck BP, Lamb HJ, Bax JJ, van der Wall EE, de Roos A. Assessment of diastolic function by cardiovascular magnetic resonance. 2002;144:198-205 (Progress cardiol.)
- Pahl E (see Shaddy et al). 2002;144:383-9 (Trial design)
- Paladini B (see Conti et al). 2002;144:630-5
- Pan M (see de Lezo et al). 2002;144:877-80
- Pandian NG (see Kuvini et al). 2002;144:165-72
- Panza JA (see Gottdiener et al). 2002;144:115-21
- Paoletti R (see Gotto and Paoletti). 2002;144:S19-20
- Papadaki OA (see Zairis et al). 2002;144:782-9
- Papademetriou V (see Wachtell et al). 2002;144:1057-64
- Paraskevaidis J (see Adamopoulos et al). 2002;144:359-64
- Parissis JT (see Adamopoulos et al). 2002;144:359-64
- Parker AB, Yusuf S, Naylor CD. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited. 2002;144:941-7 (Curriculum cardiol.)
- Parsons L (see Every et al). 2002;144:390-6
- Pasquali SK, Sanders SP, Li JS. Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. 2002;144:608-14 (Trial design)
- Patel AR (see Kuvini et al). 2002;144:165-72
- Pathak A (see Smyth et al). 2002;144:577-9 (Editorial)
- Pavlovic D (see de Lezo et al). 2002;144:877-80
- Pears J (see Olsson et al). 2002;144:1044-51
- Peci P (see Avanzini et al). 2002;144:1018-25
- Pellaton C, Kubli S, Feihl F, Waeber B. Blunted vasodilatory responses in the cutaneous microcirculation of cigarette smokers. 2002;144:269-74
- Perin EC, Silva GV, Sarmiento-Leite R, Vaughn WK, Fish RD, Ferguson JJ III. Left ventricular electromechanical mapping: preliminary evidence of electromechanical changes after successful coronary intervention. 2002;144:693-701
- Peterson ED (see Cantor et al). 2002;144:297-302

- Peuhkurinen K (see Tuomainen et al). 2002;144:870-6
- Philipp CS (see Kostis et al). 2002;144:625-9
- Phillips HR (see Hillegass et al). 2002;144:501-7
- Pick JJ (see Thury et al). 2002;144:136-43
- Pieper KS (see Mukherjee et al). 2002;144:995-1002
- Pieroni C (see Conti et al). 2002;144:630-5
- Pilote L (see Doucet et al). 2002;144:144-50
- Pilz B (see Friedrich et al). 2002;144:329-34
- Pisarikova A (see Melenovsky et al). 2002;144:e6
- Pitt B. New insights into the role of aldosterone in cardiorenal disease and the clinical implications—Introduction. 2002;144:S1
- Plokker THWM (see Walhout et al). 2002;144:180-6
- Poetsch T (see Friedrich et al). 2002;144:329-34
- Poldermans D (see Schinkel et al). 2002;144:865-9
- Poledne R (see Melenovsky et al). 2002;144:e6
- Poole-Wilson PA (see Florea et al). 2002;144:45-50
- Prabha A, Shetty M, Thomas J, Chowta N, Prabhu MV. Chelation therapy for coronary heart disease. 2002;144:e10 (Letter)
- Prabhu MV (see Prabha et al). 2002;144:e10 (Letter)
- PRAISE Investigators (see Neuberger et al). 2002;144:31-8
- Pressler ML (see Neuberger et al). 2002;144:31-8
- PRIDE Investigators (see Lee et al). 2002;144:60-7
- Prosser C (see Wong et al). 2002;144:987-94
- Puel J (see Elbaz et al). 2002;144:e7
- Punlee K (see Kittayaphong et al). 2002;144:e15

## Q

- Quesenberry C (see Hsu et al). 2002;144:404-12

## R

- Racz M (see Goldstein et al). 2002;144:561-7 (Progress cardiol.)
- Radke PW, Ortlepp JR, Merklebach-Bruse S, Kaiser A, Kronenberger S, Handt S, Hanrath P. Prevalence of *Chlamydia pneumoniae* in nonrheumatic stenotic aortic valves. 2002;144:e12 (Letter)
- Raitt MH (see Brodsky et al). 2002;144:478-84
- Ramanathan K (see Edwards et al). 2002;144:e8
- Ramappa P (see Di Carli et al). 2002;144:711-18
- Rämet ME (see Kuvini et al). 2002;144:165-72
- Ranjan R (see Al Falluji et al). 2002;144:636-41
- Rathore SS, Ordin DL, Krumholz HM. Race and sex differences in the refusal of cardiac catheterization among elderly patients hospitalized with acute myocardial infarction. 2002;144:1052-6
- Rathore SS (see Kilborn et al). 2002;144:1095-101
- Rathz DA (see Waggoner et al). 2002;144:840-6
- Rauchhaus M (see Florea et al). 2002;144:45-50
- Ravnan MC (see Matalaka et al). 2002;144:674-7
- Reddan DN. Therapy for cardiovascular disease in patients with chronic kidney disease: appropriate caution or the absence of data. 2002;144:206-7 (Editorial)
- Regar E (see Thury et al). 2002;144:136-43
- Reiner JS (see Lundergan et al). 2002;144:456-62
- RESTORE Investigators (see Gibson et al). 2002;144:130-5
- Rickli H (see Myers et al). 2002;144:719-25
- Rinaldi J-P (see Elbaz et al). 2002;144:e7
- Ritchie JL (see Watanabe et al). 2002;144:309-14
- RITZ-4 Investigators (see O'Connor et al). 2002;144:583-8 (Trial design)
- Roberts R (see Irvine et al). 2002;144:282-9
- Roberts R (see McKelvie et al). 2002;144:23-30
- Roden DM (see Anderson et al). 2002;144:769-81 (Meetings)
- Rodés J (see Tardif et al). 2002;144:589-96 (Trial design)
- Roe MT (see Mukherjee et al). 2002;144:995-1002
- Roelands JRTC (see Schinkel et al). 2002;144:865-9
- Rokkedal J (see Olsen et al). 2002;144:530-7
- Rokkedal J (see Wachtell et al). 2002;144:1057-64
- Romero M (see de Lezo et al). 2002;144:877-80



- Rosano T (see Wiecek et al). 2002;144:834-9  
Roseman JM (see Ahmed et al). 2002;144:365-72  
Rosman HS (see Klingler et al). 2002;144:51-9  
Ross AM (see Lundergan et al). 2002;144:456-62  
Rosuvastatin Investigators Group (see Olsson et al). 2002;144:1044-51  
Rosuvastatin Study Group (see Brown et al). 2002;144:1036-43  
Rowell R (see Alexander et al). 2002;144:431-9  
Ruscio M (see Colonna et al). 2002;144:796-803  
Ryan T (see Sachdev et al). 2002;144:1065-73

## S

- Sabatier R (see Elbaz et al). 2002;144:e7  
Sabatine MS (see Cooper et al). 2002;144:790-5  
Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. 2002;144:1065-73  
Saint-Jacques H (see Nguyen et al). 2002;144:549-60 (Meetings)  
Sakuma M (see Kamishirado et al). 2002;144:303-8  
Salvator A (see Mehta et al). 2002;144:1109-15  
Sammali A (see Boriani et al). 2002;144:851-7  
Sandberg KR (see McCullough et al). 2002;144:226-32  
Sanders GD (see Owens et al). 2002;144:440-8  
Sanders SP (see Pasquali et al). 2002;144:608-14 (Trial design)  
Santoro E (see Avanzini et al). 2002;144:1018-25  
Santoro G (see Conti et al). 2002;144:630-5  
Santoro GM (see Antonucci et al). 2002;144:315-22  
Santoro L (see Avanzini et al). 2002;144:1018-25  
Sanz G (see Anguera et al). 2002;144:811-17  
Sarmiento-Leite R (see Perin et al). 2002;144:693-701  
Saynina O (see Alexander et al). 2002;144:431-9  
Saynina O (see Hlatky et al). 2002;144:397-403  
Saynina O (see McDonald et al). 2002;144:413-21  
Schelbert HR (see Di Carli et al). 2002;144:711-18  
Schene AH (see van den Brink et al). 2002;144:219-25 (Trial design)  
Schertler T (see Myers et al). 2002;144:719-25  
Schiller NB. Color me variable: the irreproducible nature of color flow Doppler in mitral and aortic regurgitation. 2002;144:5-7 (Editorial)  
Schinkel AFL, Bax JJ, Boersma E, Elhendy A, Vourvouri EC, Roelandt JRTC, Poldermans D. Assessment of residual myocardial viability in regions with chronic electrocardiographic Q-wave infarction. 2002;144:865-9  
Schlenker-Herceg R (see Shaddy et al). 2002;144:383-9 (Trial design)  
Schmermund A, Möhlenkamp S, Stang A, Grönemeyer D, Seibel R, Hirsch H, Mann K, Siffert W, Lauterbach K, Siegrist J, Jöckel K-H, Erbel R, Heinz Nixdorf Recall Study Investigative Group. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. 2002;144:212-18 (Trial design)  
Schmermund A (see Bruch et al). 2002;144:538-43  
Schulz-Menger J (see Friedrich et al). 2002;144:329-34  
Schulz O, Kromer A. Cardiac troponin I: a potential marker of exercise intolerance in patients with moderate heart failure. 2002;144:351-8  
Schwitzer J (see Myers et al). 2002;144:719-25  
Segers P, Morimont P, Kolh P, Stergiopoulos N, Westerhof N, Verdonck P. Arterial elastance and heart-arterial coupling in aortic regurgitation are determined by aortic leak severity. 2002;144:568-76 (Progress cardiol.)  
Segura J (see de Lezo et al). 2002;144:877-80  
Seibel R (see Schmermund et al). 2002;144:212-18 (Trial design)  
Selby J (see Hsu et al). 2002;144:404-12  
Salem AH (see Colonna et al). 2002;144:796-803  
Semb AG (see Gullestad et al). 2002;144:847-50  
Senatore F (see Cohen et al). 2002;144:470-7  
Serruys PW (see Thury et al). 2002;144:136-43  
Sesso HD (see Orford et al). 2002;144:95-100  
Shaddy RE, Curtin EL, Sower B, Tani LY, Burr J, LaSalle B, Boucek MM, Mahony L, Hsu DT, Pahl E, Burch GH, Schlenker-Herceg R. The pediatric randomized carvedilol trial in children with chronic heart failure: rationale and design. 2002;144:383-9 (Trial design)  
Shah MR (see O'Connor et al). 2002;144:583-8 (Trial design)  
Shah S (see Klingler et al). 2002;144:51-9  
Shamim W, Yousufuddin M, Xiao HB, Flather M, Hencin M, Gibson DG, Coats AJ. Septal q waves as an indicator of risk of mortality in elderly patients with chronic heart failure. 2002;144:740-4  
Shapiro EP (see Sung et al). 2002;144:39-44  
Sharma R (see Florea et al). 2002;144:45-50  
Shetty M (see Prabha et al). 2002;144:e10 (Letter)  
Shibata M (see Koba et al). 2002;144:1026-35  
Shimodono S (see Okura et al). 2002;144:323-8  
Shinozuka A (see Akutsu et al). 2002;144:335-42  
Sianos G (see Thury et al). 2002;144:136-43  
Sica DA (see White et al). 2002;144:657-65  
Siegrist J (see Schmermund et al). 2002;144:212-18 (Trial design)  
Siffert W (see Schmermund et al). 2002;144:212-18 (Trial design)  
Sigmon KN (see Madan et al). 2002;144:151-8  
Silber HA (see Sung et al). 2002;144:39-44  
Silić N (see Čilić et al). 2002;144:1012-17  
Silke B (see McMullan et al). 2002;144:e13 (Letter)  
Silva GV (see Perin et al). 2002;144:693-701  
Silver M (see Burger et al). 2002;144:1102-8  
Simek J (see Melenovsky et al). 2002;144:e6  
Singer L (see Mehta et al). 2002;144:1109-15  
Sitges M (see Anguera et al). 2002;144:811-17  
Sivasankaran S (see Bhat et al). 2002;144:1074-80  
Sivasubramanian R (see Jackson et al). 2002;144:259-68  
Skane AC (see Chauhan et al). 2002;144:858-64  
Skärål R (see Gullestad et al). 2002;144:847-50  
Skrha J (see Melenovsky et al). 2002;144:e6  
Slager CJ (see Thury et al). 2002;144:136-43  
Slater JC (see Holubkov et al). 2002;144:826-33  
Smit AC (see Madan et al). 2002;144:151-8  
Smith G (see Wachtell et al). 2002;144:1057-64  
Smyth SS, Pathak A, Stouffer GA. In-stent restenosis: more fuel for the fire. 2002;144:577-9 (Editorial)  
Sobashima A (see Matsui et al). 2002;144:101-7  
Soler JS (see Figueras et al). 2002;144:251-8  
Solomon AJ (see Kilborn et al). 2002;144:1095-101  
Somerville J (see Li et al). 2002;144:173-9  
Søndergaard E, Møller JE, Egstrup K. Relationship between vascular dysfunction in peripheral arteries and ischemic episodes during daily life in patients with ischemic heart disease and hypercholesterolemia. 2002;144:108-14  
Southworth H (see Olsson et al). 2002;144:1044-51  
Sower B (see Shaddy et al). 2002;144:383-9 (Trial design)  
Speidl WS, Graf S, Hornykewycz S, Nikfarjam M, Niessner A, Zorn G, Wojta J, Huber K. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. 2002;144:449-55  
Spencer FA (see Jackson et al). 2002;144:259-68  
St John Sutton M (see Gottdiener et al). 2002;144:115-21  
Stack RS (see Hillegass et al). 2002;144:501-7  
Stambler B (see Lopez-Jimenez et al). 2002;144:687-92  
Stang A (see Schmermund et al). 2002;144:212-18 (Trial design)  
Stavek P (see Melenovsky et al). 2002;144:e6  
Stebbins AL (see Anderson et al). 2002;144:81-8  
Stedman M (see Orford et al). 2002;144:95-100  
Stefanidis AS (see Zairis et al). 2002;144:782-9  
Steg P-G (see Kereiakes et al). 2002;144:615-24  
Steg PG (see Elbaz et al). 2002;144:e7  
Stein EA. Management of dyslipidemia in the high-risk patient. 2002;144:S43-50  
Stender S (see Olsson et al). 2002;144:1044-51

- Stergopoulos N (see Segers et al). 2002;144:568-76 (Progress cardi-  
diol.)  
Stewart KJ (see Sung et al). 2002;144:39-44  
Stewart RAH (see Edwards et al). 2002;144:e8  
Stoddard MF (see Mitchell et al). 2002;144:e9  
Stouffer GA (see Smyth et al). 2002;144:577-9 (Editorial)  
Strathdee SA (see Meng et al). 2002;144:642-8  
Strobel GG (see Horne et al). 2002;144:491-500  
Struthers AD. Aldosterone: cardiovascular assault. 2002;144:S2-7  
Studio per una Terapia Antipertensiva Razionale Investigators (see  
Avanzini et al). 2002;144:726-32  
Su M-J (see Lai et al). 2002;144:485-90  
Sung J, Ouyang P, Bacher AC, Turner KL, DeRegis JR, Hees PS,  
Silber HA, Shapiro EP, Stewart KJ. Peripheral endothelium-  
dependent flow-mediated vasodilatation is associated with left  
ventricular mass in older persons with hypertension. 2002;144:  
39-44  
Super DM (see Mehta et al). 2002;144:1109-15  
Suzuki H (see Koba et al). 2002;144:1026-35

## T

- Takahashi W (see Hongo et al). 2002;144:122-9  
Takayanagi K (see Inoue et al). 2002;144:e5  
Takayanagi K (see Kamishirado et al). 2002;144:303-8  
Takenaka H (see Akutsu et al). 2002;144:335-42  
Tanaka S (see Matsui et al). 2002;144:101-7  
Tani LY (see Shaddy et al). 2002;144:383-9 (Trial design)  
Tardif J-C, Grégoire J, Lespérance J, Lambert J, L'Allier PL, Rodés J,  
Anderson T, Blue JW, Imus J, Heinonen T. Design features of the  
Avasimibe and Progression of coronary Lesions assessed by  
intravascular UltraSound (A-PLUS) clinical trial.  
2002;144:589-96 (Trial design)  
Tcheng JE (see Hillegeass et al). 2002;144:501-7  
Tcheng JE (see Madan et al). 2002;144:151-8  
Teirstein P (see Kereiakes et al). 2002;144:615-24  
Teo KK (see McKelvie et al). 2002;144:23-30  
Teo KK (see Wong et al). 2002;144:987-94  
Thadani U. Selective L-type, T-type, and nonspecific calcium-chan-  
nel blockers for stable angina pectoris. 2002;144:8-10 (Editorial)  
Tharakan JM (see Bhat et al). 2002;144:1074-80  
Thérout P (see Cohen et al). 2002;144:470-7  
Thom D (see Every et al). 2002;144:390-6  
Thomas J (see Prabha et al). 2002;144:e10 (Letter)  
Thompson TD (see Gilchrist et al). 2002;144:73-80  
Thury A, van Langenhove G, Carlier SG, Albertal M, Kozuma K,  
Regar E, Sianos G, Wentzel JJ, Krams R, Slager CJ, Piek JJ,  
Serruys PW. DEBATE Investigators. High shear stress after suc-  
cessful balloon angioplasty is associated with restenosis and  
target lesion revascularization. 2002;144:136-43  
Thygesen K (see Newby et al). 2002;144:957-80 (Meetings)  
Tiefenbrunn A (see Mathew et al). 2002;144:463-9  
Tijssen JGP (see de Milliano et al). 2002;144:e3  
TIMI Study Group (see Angeja et al). 2002;144:649-56  
Titus T (see Bhat et al). 2002;144:1074-80  
Toccafondi S (see Conti et al). 2002;144:630-5  
Tognoni G (see Avanzini et al). 2002;144:726-32, 1018-25  
TONE Cooperative Research Group (see Kostis et al). 2002;144:  
625-9  
Tong W (see Meng et al). 2002;144:642-8  
Topol EJ (see Anderson et al). 2002;144:81-8  
Topol EJ (see Mukherjee et al). 2002;144:995-1002  
Torre G (see Burger et al). 2002;144:1102-8  
Torri V (see Avanzini et al). 2002;144:726-32  
Trapani M (see Antoniucci et al). 2002;144:315-22  
Trichon B (see Nguyen et al). 2002;144:549-60 (Meetings)  
Trichon BH, O'Connor CM. Secondary mitral and tricuspid regur-  
gitation accompanying left ventricular systolic dysfunction: is it  
important, and how is it treated? 2002;144:373-6 (Editorial)  
Trillo RA (see Mitchell et al). 2002;144:e9

- Truman A (see Hsu et al). 2002;144:404-12  
Tseng C-D (see Lai et al). 2002;144:485-90  
Tseng Y-Z (see Lai et al). 2002;144:485-90  
Tu JV (see Austin et al). 2002;144:290-6  
Tuomainen P, Vanninen E, Halonen P, Peuhkurinen K. Character-  
ization of the warm-up phenomenon in patients with coronary  
artery disease. 2002;144:870-6  
Tuomilehto J (see Olsson et al). 2002;144:1044-51  
Turner KL (see Sung et al). 2002;144:39-44

## U

- Uchida T (see Kamishirado et al). 2002;144:303-8  
Uchikawa S (see Hongo et al). 2002;144:122-9  
Ueland T (see Gullestad et al). 2002;144:847-50  
Uhlich F (see Friedrich et al). 2002;144:329-34  
Uratsu C (see Hsu et al). 2002;144:404-12  
Urushibata K (see Hongo et al). 2002;144:122-9

## V

- Valenti R (see Antoniucci et al). 2002;144:315-22  
Van de Werf F (see Kereiakes et al). 2002;144:615-24  
van den Brink RHS, van Melle JP, Honig A, Schene AH, Crijns HJGM,  
Lambert FPG, Ormel J, MIND-IT Investigators. Treatment of  
depression after myocardial infarction and the effects on car-  
diac prognosis and quality of life: rationale and outline of the  
Myocardial Infarction and Depression-Intervention Trial (MIND-  
IT). 2002;144:219-25 (Trial design)  
van der Wall EE (see Agema et al). 2002;144:760-8 (Progress car-  
diol.)  
van der Wall EE (see Paelinck et al). 2002;144:198-205 (Progress  
cardiol.)  
van Eck-Smit BLF (see de Milliano et al). 2002;144:e3  
van Langenhove G (see Thury et al). 2002;144:136-43  
van Melle JP (see van den Brink et al). 2002;144:219-25 (Trial  
design)  
Van Mieghem W (see Cohen et al). 2002;144:470-7  
van Zwieten PA (see de Milliano et al). 2002;144:e3  
Vanninen E (see Tuomainen et al). 2002;144:870-6  
Vaughn WK (see Perin et al). 2002;144:693-701  
Veinot J (see Glover et al). 2002;144:702-9  
Verdonck P (see Segers et al). 2002;144:568-76 (Progress cardi-  
ol.)  
Vitale K (see Lopez-Jimenez et al). 2002;144:687-92  
Vlachos HA (see Holubkov et al). 2002;144:826-33  
Vlahov D (see Meng et al). 2002;144:642-8  
Vokonas P (see Orford et al). 2002;144:95-100  
von Känel R, Mills PJ, Ziegler MG, Dimsdale JE. Effect of  $\beta_2$ -  
adrenergic receptor functioning and increased norepinephrine  
on the hypercoagulable state with mental stress. 2002;144:  
68-72  
Vourvouri EC (see Schinkel et al). 2002;144:865-9

## W

- Wachtell K, Dahlöf B, Rokkedal J, Papademetriou V, Nieminen MS,  
Smith G, Gerds E, Boman K, Bella JN, Devereux RB. Change of  
left ventricular geometric pattern after 1 year of antihyperten-  
sive treatment: the Losartan Intervention For Endpoint reduc-  
tion in hypertension (LIFE) study. 2002;144:1057-64  
Wachtell K (see Olsen et al). 2002;144:530-7  
Waeber B (see Pellaton et al). 2002;144:269-74  
Wagner D (see Myers et al). 2002;144:719-25  
Wagner GS (see Anderson et al). 2002;144:81-8  
Wagner GS (see Goodman et al). 2002;144:243-50  
Wagoner LE, Craft LL, Zengel P, McGuire N, Rathz DA, Dorn GW II,  
Liggett SB. Polymorphisms of the  $\beta_1$ -adrenergic receptor pre-  
dict exercise capacity in heart failure. 2002;144:840-6  
Wahi S (see Najos-Valencia et al). 2002;144:516-23

- Walhout RJ, Lekkerkerker JC, Ernst SMPG, Hutter PA, Plokker THWM, Meijboom EJ. Angioplasty for coarctation in different aged patients. 2002;144:180-6
- Walker BD (see Chauhan et al). 2002;144:858-64
- Wallentin L (see Kereiakes et al). 2002;144:615-24
- Walsh CR, Cupples LA, Levy D, Kiel DP, Hannan M, Wilson PWF, O'Donnell CJ. Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: the Framingham Heart Study. 2002;144:733-9
- Walsh CR, O'Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DM. Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. 2002;144:1003-11
- Wang CH, Kuo L-T, Hung MJ, Cherng W-J. Coronary vasospasm as a possible cause of elevated cardiac troponin I in patients with acute coronary syndrome and insignificant coronary artery disease. 2002;144:275-81
- Watanabe CT, Maynard C, Ritchie JL. Short-term outcomes after percutaneous coronary intervention: effects of stenting and institutional volume shifts. 2002;144:309-14
- Weaver D (see Every et al). 2002;144:390-6
- Weaver WD (see Anderson et al). 2002;144:81-8
- Weber MA. Clinical implications of aldosterone blockade. 2002;144:S12-18
- Weissman NJ (see Gottdiener et al). 2002;144:115-21
- Wentzel JJ (see Thury et al). 2002;144:136-43
- Wertheimer JH (see Neuberger et al). 2002;144:31-8
- West TM (see Edwards et al). 2002;144:e8
- Westerhof N (see Segers et al). 2002;144:568-76 (Progress cardiol.)
- Whellan DJ, O'Connor CM. The state of exercise training: a need for action. 2002;144:1-4 (Editorial)
- White HD. Things ain't what they used to be: impact of a new definition of myocardial infarction. 2002;144:933-7 (Editorial)
- White HD (see Anderson et al). 2002;144:81-8
- White HD (see Cohen et al). 2002;144:470-7
- White HD (see Edwards et al). 2002;144:e8
- White HD (see Mukherjee et al). 2002;144:995-1002
- White WB, Sica DA, Calhoun D, Mansoor GA, Anders RJ. Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. 2002;144:657-65
- Wichterle D (see Melenovsky et al). 2002;144:e6
- Wieczorek SJ, Wu AHB, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, Hager D, Gardetto N, Chiu A, Bailly KR, Maisel A. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. 2002;144:834-9
- Wiklund O (see Olsson et al). 2002;144:1044-51
- Wilkoff BL (see Lopez-Jimenez et al). 2002;144:687-92
- Williams DO (see Holubkov et al). 2002;144:826-33
- Wilpshaar JW (see Olsson et al). 2002;144:1044-51
- Wilson AC (see Al Falluji et al). 2002;144:636-41
- Wilson AC (see Kostis et al). 2002;144:625-9
- Wilson PWF (see Walsh et al). 2002;144:733-9

- Wimbush F (see Klingler et al). 2002;144:51-9
- Wojta J (see Speidl et al). 2002;144:449-55
- Wong BYL, Gnarp J, Teo KK, Ohman EM, Prosser C, Gibler WB, Langer A, Chang W-C, Armstrong PW. Does chronic *Chlamydia pneumoniae* infection increase the risk of myocardial injury? Insights from patients with non-ST-elevation acute coronary syndromes. 2002;144:987-94
- Wu AHB (see Apple et al). 2002;144:981-6 (Meetings)
- Wu AHB (see Wieczorek et al). 2002;144:834-9
- Wu KC (see Meng et al). 2002;144:642-8
- Wu KK (see Folsom et al). 2002;144:233-8

## X

- Xiao HB (see Shamim et al). 2002;144:740-4

## Y

- Yadav JS (see Mukherjee and Yadav). 2002;144:753-9 (Curriculum cardiol.)
- Yadav JS (see Mukherjee et al). 2002;144:995-1002
- Yaguchi I (see Inoue et al). 2002;144:e5
- Yamanaka H (see Akutsu et al). 2002;144:335-42
- Yarzebski J (see Jackson et al). 2002;144:259-68
- Yee R (see Chauhan et al). 2002;144:858-64
- Yeh H-M (see Lai et al). 2002;144:485-90
- Yndestad A (see Gullestad et al). 2002;144:847-50
- Yock PG (see Okura et al). 2002;144:323-8
- Yoon C (see Lopez-Jimenez et al). 2002;144:687-92
- Young DR (see Allen et al). 2002;144:678-86
- Yousufuddin M (see Shamim et al). 2002;144:740-4
- Yung T-c (see Cheung et al). 2002;144:159-64
- Yusuf S (see McKelvie et al). 2002;144:23-30
- Yusuf S (see Parker et al). 2002;144:941-7 (Curriculum cardiol.)

## Z

- Zairis MN, Manousakis SJ, Stefanidis AS, Papadaki OA, Andrikopoulos GK, Olympios CD, Hadjissavas JJ, Argyrakis SK, Foussas SG. C-Reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. 2002;144:782-9
- Zannad F, Gille B, Grentzinger A, Bruntz J-F, Hammadi M, Boivin J-M, Hanotin C, Igau B, Drouin P. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. 2002;144:508-15
- Zannoli R (see Boriani et al). 2002;144:851-7
- Zengel P (see Wagoner et al). 2002;144:840-6
- Zidar JP (see Cantor et al). 2002;144:297-302
- Ziegler MG (see von Känel et al). 2002;144:68-72
- Zorn G (see Speidl et al). 2002;144:449-55
- Zwinderman AH (see Agema et al). 2002;144:760-8 (Progress cardiol.)

# Subject index\*

## A

### Abciximab

Abciximab therapy improves 1-month survival rate in unscheduled patients with acute myocardial infarction undergoing routine infarct artery stent implantation (Antoniucci et al). 2002;144:315-22

### ACE inhibitors; see Angiotensin-converting enzyme inhibitors

### Acromegaly

Impact of disease activity on left ventricular performance in patients with acromegaly (Bruch et al). 2002;144:538-43

### Adrenergic beta-antagonists

Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease (McCullough et al). 2002;144:226-32

### Age factors; see Epidemiologic factors

### Aldosterone

Aldosterone: cardiovascular assault (Struthers). 2002;144:S2-7  
Clinical implications of aldosterone blockade (Weber). 2002;144:S12-18

New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone (Funder). 2002;144:S8-11

New insights into the role of aldosterone in cardiorenal disease and the clinical implications—Introduction (Pitt). 2002;144:S1

### American College of Cardiology

Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations (Newby et al). 2002;144:957-80 (Meetings)

European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials (Apple et al). 2002;144:981-6 (Meetings)

Highlights from the American College of Cardiology Annual Scientific Sessions 2002: March 17 to 20, 2002 (Nguyen et al). 2002;144:549-60 (Meetings)

Things ain't what they used to be: impact of a new definition of myocardial infarction (White). 2002;144:933-7 (Editorial)

### Amiodarone

Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation (Kilborn et al). 2002;144:1095-101

### Amyloidosis

Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis (Hongo et al). 2002;144:122-9

### Anemia

Effect of anemia on 1-year mortality in patients with acute myocardial infarction (Al Falluji et al). 2002;144:636-41

### Aneurysm, ruptured

Emergency endovascular interventions for ruptured thoracic and abdominal aortic aneurysms (Doss et al). 2002;144:544-8

### Angina, unstable. see also Myocardial ischemia

A combination of troponin T and 12-lead electrocardiography: a valuable tool for early prediction of long-term mortality in patients with chest pain without ST-segment elevation (Jernberg and Lindahl). 2002;144:804-10

Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina (Anguera et al). 2002;144:811-17

Low-molecular-weight heparin therapy for non-ST-elevation

acute coronary syndromes and during percutaneous coronary intervention: an expert consensus (Kereiakes et al). 2002;144:615-24

Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina (Colonna et al). 2002;144:796-803

### Angina pectoris

Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry (Holubkov et al). 2002;144:826-33

Effectiveness of a novel serotonin blocker, sarpgrelate, for patients with angina pectoris (Kinugawa et al). 2002;144:e1

Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial (Lee et al). 2002;144:60-7

Selective L-type, T-type, and nonspecific calcium-channel blockers for stable angina pectoris (Thadani). 2002;144:8-10 (Editorial)

### Angioplasty, balloon

Angioplasty for coarctation in different aged patients (Walhout et al). 2002;144:180-6

High shear stress after successful balloon angioplasty is associated with restenosis and target lesion revascularization (Thury et al). 2002;144:136-43

Impact of deep vessel wall injury and vessel stretching on subsequent arterial remodeling after balloon angioplasty: a serial intravascular ultrasound study (Okura et al). 2002;144:323-8

A new thrombolytic agent, monteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: initial results of the COMbining Monteplase with Angioplasty (COMA) trial (Inoue et al). 2002;144:e5

Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women (Cantor et al). 2002;144:297-302

### Angioplasty, transluminal, percutaneous coronary

Effects of hospital volume on long-term outcomes after percutaneous transluminal coronary angioplasty after acute myocardial infarction (Doucet et al). 2002;144:144-50

How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction (Lundergan et al). 2002;144:456-62

Impact of cardiac catheterization-percutaneous coronary intervention timing on in-hospital mortality (Goldstein et al). 2002;144:561-7 (Progress cardiol.)

### Angiotensin-converting enzyme

Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: identifying the guideposts for navigating the genetics landscape (Kraus and Hauser). 2002;144:747-9 (Editorial)

Association of angiotensin-converting enzyme DD genotype with blood pressure sensitivity to weight loss (Kostis et al). 2002;144:625-9

A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias (Agema et al). 2002;144:760-8 (Progress cardiol.)

### Angiotensin-converting enzyme inhibitors

Aldosterone: cardiovascular assault (Struthers). 2002;144:S2-7  
Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure (Ahmed et al). 2002;144:365-72

Risks and benefits of early treatment of acute myocardial infarction with an angiotensin-converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI-3 database (Avanzini et al). 2002;144:1018-25

\*July, pp. 1-186; August, pp. 187-372; September, pp. 373-560; October, pp. 561-744; November pp. 745-932; December, pp. 933-1142.



# Anti-arrhythmia agents

Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death (Heidenreich et al). 2002;144:422-30

# Anticholesteremic agents; see Hydroxymethylglutaryl-CoA reductase inhibitors

# Antihypertensive agents

Oral antihypertensive trial design and analysis under the pediatric exclusivity provision (Pasquali et al). 2002;144:608-14 (Trial design)

Simple, shared guidelines raise the quality of antihypertensive treatment in routine care (Avanzini et al). 2002;144:726-32

# Antiplatelet therapy; see Platelet aggregation inhibitors

# Aorta

Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: the Framingham Heart Study (Walsh et al). 2002;144:733-9

Emergency endovascular interventions for ruptured thoracic and abdominal aortic aneurysms (Doss et al). 2002;144:544-8

# Aortic coarctation

Angioplasty for coarctation in different aged patients (Walhout et al). 2002;144:180-6

# Aortic valve insufficiency

Arterial elastance and heart-arterial coupling in aortic regurgitation are determined by aortic leak severity (Segers et al). 2002;144:568-76 (Progress cardiol.)

Color me variable: the irreproducible nature of color flow Doppler in mitral and aortic regurgitation (Schiller). 2002;144:5-7 (Editorial)

Testing the test: the reliability of echocardiography in the sequential assessment of valvular regurgitation (Gottdiener et al). 2002;144:115-21

# Aortic valve stenosis

Prevalence of *Chlamydia pneumoniae* in nonrheumatic stenotic aortic valves (Radke et al). 2002;144:e12 (Letter)

Quantification of valvular aortic stenosis by magnetic resonance imaging (Friedrich et al). 2002;144:329-34

# Appetite depressants

Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies (Sachdev et al). 2002;144:1065-73

Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction (Zannad et al). 2002;144:508-15

# Arrhythmia. see also Atrial fibrillation and flutter

Cardiac rhythm and symptomatic arrhythmia in right atrial isomerism (Cheung et al). 2002;144:159-64

Common electrocardiographic artifacts mimicking arrhythmias in ambulatory monitoring (Marquez et al). 2002;144:187-97 (Curriculum cardiol.)

Demise of the routine electrophysiologic study for survivors of life-threatening ventricular arrhythmias (Curtis). 2002;144:380-2 (Editorial)

In search of left septal fascicular block (MacAlpin). 2002;144:948-56 (Progress cardiol.)

A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation (Hershberger et al). 2002;144:1081-6

Prognostic value of baseline electrophysiology studies in patients with sustained ventricular tachyarrhythmia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial (Brodsky et al). 2002;144:478-84

Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease (Every et al). 2002;144:390-6

# Arrhythmia, therapy

Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study (Krittayaphong et al). 2002;144:e15

Effect of nesiritide (B-type natriuretic peptide) and dobutamine

on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study (Burger et al). 2002;144:1102-8

Life after a ventricular arrhythmia (Hsu et al). 2002;144:404-12

Management of ventricular arrhythmias in diverse populations in California (Alexander et al). 2002;144:431-9

Quality of life in patients with life-threatening arrhythmias: does choice of therapy make a difference? (Exner). 2002;144:208-11 (Editorial)

Quality of life in the Canadian Implantable Defibrillator Study (CIDS) (Irvine et al). 2002;144:282-9

Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995 (McDonald et al). 2002;144:413-21

Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995 (Hlatky et al). 2002;144:397-403

# Arteriosclerosis

Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: the Framingham Heart Study (Walsh et al). 2002;144:733-9

Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study (Schmermund et al). 2002;144:212-18 (Trial design)

C-Reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study (Folsom et al). 2002;144:233-8

Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification (Mukherjee and Yadav). 2002;144:753-9 (Curriculum cardiol.)

Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors (Meng et al). 2002;144:642-8

Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial (Tardif et al). 2002;144:589-96 (Trial design)

# Aspirin

Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease (McCullough et al). 2002;144:226-32

Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): a population-based perspective (Jackson et al). 2002;144:259-68

Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study (Cohen et al). 2002;144:470-7

# Atenolol

Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study (Krittayaphong et al). 2002;144:e15

# Atorvastatin

Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia (Mcenovsky et al). 2002;144:e6

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia (Olsson et al). 2002;144:1044-51

Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS) (Matalka et al). 2002;144:674-7

# Atrial fibrillation and flutter

Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation (Kilborn et al). 2002;144:1095-101

Association of the human minK gene 38G allele with atrial

- fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation (Lai et al). 2002;144:485-90
- Effect of atrial flutter on exercise tolerance in patients with grown-up congenital heart (GUCH) (Li et al). 2002;144:173-9
- Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial (AF-CHF Trial Investigators). 2002;144:597-607 (Trial design)
- Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter (Khan). 2002;144:11-22 (Curriculum cardiol.). Correction 2002;144:232
- Transvenous internal cardioversion for atrial fibrillation: a randomized comparison between catheters with different coil length (Boriani et al). 2002;144:851-7

#### **Atrial septal defect; see Heart defects, congenital**

#### **Autonomic nervous system**

- Autonomic alterations in cocaine-exposed infants (Mehta et al). 2002;144:1109-15
- Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure (de Milliano et al). 2002;144:e3
- Exercise testing for assessment of autonomic function (Lauer). 2002;144:580-2 (Editorial)
- Heart rate recovery after exercise is related to the insulin resistance syndrome and heart rate variability in elderly men (Lind and Andrén). 2002;144:666-72
- Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis (Hongo et al). 2002;144:122-9

#### **Avasimibe**

- Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial (Tardif et al). 2002;144:589-96 (Trial design)

## **B**

#### **B-natriuretic peptide; see Natriuretic peptide, brain**

#### **Beta adrenergic receptors; see Receptors, adrenergic, beta**

#### **Beta blockers; see Adrenergic beta-antagonists**

#### **Blood coagulation**

- Effect of  $\beta_2$ -adrenergic receptor functioning and increased nor-epinephrine on the hypercoagulable state with mental stress (von Känel et al). 2002;144:68-72
- Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications (Hillegeass et al). 2002;144:501-7
- Relationship between hematocrit, primary hemostasis, and cardiovascular disease in athletes (Lippi et al). 2002;144:e14 (Letter)

#### **Body surface area**

- Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women (Cantor et al). 2002;144:297-302

#### **Bundle-branch block**

- In search of left septal fascicular block (MacAlpin). 2002;144:948-56 (Progress cardiol.)

## **C**

#### **C-reactive protein**

- C-Reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study (Folsom et al). 2002;144:233-8
- C-Reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction (Zairis et al). 2002;144:782-9

- Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitors on serum C-reactive protein levels: possible implications (McMullan et al). 2002;144:e13 (Letter)

- Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention (Horne et al). 2002;144:491-500

- High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease (Speidl et al). 2002;144:449-55

#### **CABG; see Coronary artery bypass**

#### **Cachexia**

- The cardiac component of cardiac cachexia (Florea et al). 2002;144:45-50

#### **Calcinosis, arterial; see Arteriosclerosis**

#### **Calcium channel blockers**

- Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial (Lee et al). 2002;144:60-7

- Selective L-type, T-type, and nonselective calcium-channel blockers for stable angina pectoris (Thadani). 2002;144:8-10 (Editorial)

#### **Cardiac repolarization**

- Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management (Anderson et al). 2002;144:769-81 (Meetings)

#### **Cardiomyopathy, congestive**

- Echocardiography-derived variables predict outcome in patients with nonischemic dilated cardiomyopathy with or without a restrictive filling pattern (Faris et al). 2002;144:343-50

- Effects of exercise training on left ventricular volumes and function in patients with nonischemic cardiomyopathy: application of magnetic resonance myocardial tagging (Myers et al). 2002;144:719-25

- Genetics in heart failure: practical incorporation of this new biologic dimension (Donahue et al). 2002;144:938-40 (Editorial)

- Impact of disease activity on left ventricular performance in patients with acromegaly (Bruch et al). 2002;144:538-43

- A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation (Hershberger et al). 2002;144:1081-6

#### **Cardiovascular disease**

- Aldosterone: cardiovascular assault (Struthers). 2002;144:S2-7
- Clinical implications of aldosterone blockade (Weber). 2002;144:S12-18

- New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone (Funder). 2002;144:S8-11

- New insights into the role of aldosterone in cardiorenal disease and the clinical implications—Introduction (Pitt). 2002;144:S1

- Relationship between hematocrit, primary hemostasis, and cardiovascular disease in athletes (Lippi et al). 2002;144:e14 (Letter)

- Therapy for cardiovascular disease in patients with chronic kidney disease: appropriate caution or the absence of data (Reddan). 2002;144:206-7 (Editorial)

- Third Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. 2002;144:881-932 (Meetings)

#### **Cardioversion; see Defibrillators, implantable; Electric countershock**

#### **Carotid arteries**

- Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification (Mukherjee and Yadav). 2002;144:753-9 (Curriculum cardiol.)

#### **Carvedilol**

- The pediatric randomized carvedilol trial in children with

chronic heart failure: rationale and design (Shaddy et al). 2002;144:383-9 (Trial design)

#### Case management

Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial (Allen et al). 2002;144:678-86

#### Catheterization

Impact of cardiac catheterization-percutaneous coronary intervention timing on in-hospital mortality (Goldstein et al). 2002;144:561-7 (Progress cardiol.)

Race and sex differences in the refusal of cardiac catheterization among elderly patients hospitalized with acute myocardial infarction (Rathore et al). 2002;144:1052-6

Transvenous internal cardioversion for atrial fibrillation: a randomized comparison between catheters with different coil length (Boriani et al). 2002;144:851-7

#### Cerebrovascular accident

Third Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. 2002;144:881-932 (Meetings)

#### Chelation therapy

Chelation therapy for coronary heart disease (Prabha et al) (Letter); (Ernst) (Reply). 2002;144:e10, e11

#### Chest pain. *see also* Angina, unstable; Angina pectoris

Effectiveness of a multidisciplinary chest pain unit for the assessment of coronary syndromes and risk stratification in the Florence area (Conti et al). 2002;144:630-5

Perceptions of chest pain differ by race (Klingler et al). 2002;144:51-9

Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors (Čulić et al). 2002;144:1012-17

#### Child

Oral antihypertensive trial design and analysis under the pediatric exclusivity provision (Pasquali et al). 2002;144:608-14 (Trial design)

The pediatric randomized carvedilol trial in children with chronic heart failure: rationale and design (Shaddy et al). 2002;144:383-9 (Trial design)

#### *Chlamydia pneumoniae*

Does chronic *Chlamydia pneumoniae* infection increase the risk of myocardial injury? Insights from patients with non-ST-elevation acute coronary syndromes (Wong et al). 2002;144:987-94

Prevalence of *Chlamydia pneumoniae* in nonrheumatic stenotic aortic valves (Radke et al). 2002;144:e12 (Letter)

#### Cholesterol, serum; *see* Hypercholesterolemia and hyperlipidemia; Lipoproteins, HDL/LDL cholesterol

#### Cilostazol

Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis (Kamishirado et al). 2002;144:303-8

#### Coagulation, blood; *see* Blood coagulation

#### Coarctation of aorta; *see* Aortic coarctation

#### Cocaine

Autonomic alterations in cocaine-exposed infants (Mehta et al). 2002;144:1109-15

#### Commissurotomy

Comparison of percutaneous transmittal commissurotomy with Inoue balloon technique and metallic commissurotomy: immediate and short-term follow-up results of a randomized study (Bhat et al). 2002;144:1074-80

#### Congenital heart defects; *see* Heart defects, congenital

#### Congestive heart failure; *see* Cardiomyopathy, congestive; Heart failure, congestive

#### Coronary artery bypass

In-hospital outcome of acute myocardial infarction in patients with prior coronary artery bypass surgery (Mathew et al). 2002;144:463-9

#### Coronary disease

Cardiologists' discussions about sexuality with patients with

chronic coronary artery disease (Bedell et al). 2002;144:239-42

Characterization of the warm-up phenomenon in patients with coronary artery disease (Tuomainen et al). 2002;144:870-6

Development and validation of a simple exercise test score for use in women with symptoms of suspected coronary artery disease (Morise et al). 2002;144:818-25

Effectiveness of a multidisciplinary chest pain unit for the assessment of coronary syndromes and risk stratification in the Florence area (Conti et al). 2002;144:630-5

High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease (Speidl et al). 2002;144:449-55

Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease (Koba et al). 2002;144:1026-35

#### Coronary disease, epidemiology

C-Reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study (Folsom et al). 2002;144:233-8

A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the Normative Aging Study (Orford et al). 2002;144:95-100

Coronary vascular dysfunction in premenopausal women with diabetes mellitus (Di Carli et al). 2002;144:711-18

Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease (Every et al). 2002;144:390-6

#### Coronary disease, therapy

Chelation therapy for coronary heart disease (Prabha et al) (Letter); (Ernst) (Reply). 2002;144:e10, e11

High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease (Gotto). 2002;144:S33-42

Management of dyslipidemia in the high-risk patient (Stein). 2002;144:S43-50

New options in lipid management—can we extend the benefits of current therapy?—Introduction (Gotto and Paoletti). 2002;144:S19-20

Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial (Allen et al). 2002;144:678-86

Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (Istvan). 2002;144:S27-32

What do the statins tell us? (LaRosa). 2002;144:S21-6

#### Coronary restenosis

Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention (Horne et al). 2002;144:491-500

High shear stress after successful balloon angioplasty is associated with restenosis and target lesion revascularization (Thury et al). 2002;144:136-43

Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation (Glover et al). 2002;144:702-9

In-stent restenosis: more fuel for the fire (Smyth et al). 2002;144:S77-9 (Editorial)

A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias (Agema et al). 2002;144:760-8 (Progress cardiol.)

#### Coronary vessels

Coronary vasospasm as a possible cause of elevated cardiac troponin I in patients with acute coronary syndrome and insignificant coronary artery disease (Wang et al). 2002;144:275-81

High shear stress after successful balloon angioplasty is associated with restenosis and target lesion revascularization (Thury et al). 2002;144:136-43

Impact of deep vessel wall injury and vessel stretching on subsequent arterial remodeling after balloon angioplasty: a

serial intravascular ultrasound study (Okura et al). 2002;144:323-8

Increased myocardial ischemia after food is not explained by endothelial dysfunction (Edwards et al). 2002;144:e8

Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women (Cantor et al). 2002;144:297-302

#### Corrections

Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter (Khan) (2002;144:11-22). 2002;144:232

#### Correspondence; see Letters to the Editor

#### Costs and cost analysis

Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator (Owens et al). 2002;144:440-8

Health values before and after pacemaker implantation (Lopez-Jimenez et al). 2002;144:687-92

#### Creatinine

Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction (Walsh et al). 2002;144:1003-11

#### Cytokines

Effect of thalidomide in patients with chronic heart failure (Gullestad et al). 2002;144:847-50

Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina (Anguera et al). 2002;144:811-17

Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy (Adamopoulos et al). 2002;144:359-64

## D

#### Death; see Mortality

#### Defibrillators, implantable

Demise of the routine electrophysiologic study for survivors of life-threatening ventricular arrhythmias (Curtis). 2002;144:380-2 (Editorial)

Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator (Owens et al). 2002;144:440-8

Life after a ventricular arrhythmia (Hsu et al). 2002;144:404-12

Management of ventricular arrhythmias in diverse populations in California (Alexander et al). 2002;144:431-9

Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death (Heidenreich et al). 2002;144:422-30

Prognostic value of baseline electrophysiology studies in patients with sustained ventricular tachyarrhythmia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial (Brodsky et al). 2002;144:478-84

Quality of life in patients with life-threatening arrhythmias: does choice of therapy make a difference? (Exner). 2002;144:208-11 (Editorial)

Quality of life in the Canadian Implantable Defibrillator Study (CIDS) (Irvine et al). 2002;144:282-9

Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease (Every et al). 2002;144:390-6

Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995 (McDonald et al). 2002;144:413-21

Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995 (Hlatky et al). 2002;144:397-403

#### Depression

Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial Infarction and Depression-Intervention Trial (MIND-IT) (van den Brink et al). 2002;144:219-25 (Trial design)

#### Diabetes mellitus

Coronary vascular dysfunction in premenopausal women with diabetes mellitus (Di Carli et al). 2002;144:711-18

Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy (Angeja et al). 2002;144:649-56

#### Diagnostic errors

A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario (Austin et al). 2002;144:290-6

#### Diastole

Assessment of diastolic function by cardiovascular magnetic resonance (Paelinck et al). 2002;144:198-205 (Progress cardiol.)

Determinants of tissue Doppler measures of regional diastolic function during dobutamine stress echocardiography (Najos-Valencia et al). 2002;144:516-23

#### Dilated cardiomyopathy; see Cardiomyopathy, congestive

#### Diuretics

Diuretic resistance predicts mortality in patients with advanced heart failure (Neuberg et al). 2002;144:31-8

#### Dobutamine

Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study (Burger et al). 2002;144:1102-8

#### Dobutamine echocardiography; see Echocardiography, stress

## E

#### Echocardiography

Echocardiography-derived variables predict outcome in patients with nonischemic dilated cardiomyopathy with or without a restrictive filling pattern (Faris et al). 2002;144:343-50

Testing the test: the reliability of echocardiography in the sequential assessment of valvular regurgitation (Gottdiener et al). 2002;144:115-21

#### Echocardiography, Doppler

Color me variable: the irreproducible nature of color flow Doppler in mitral and aortic regurgitation (Schiller). 2002;144:5-7 (Editorial)

Determinants of tissue Doppler measures of regional diastolic function during dobutamine stress echocardiography (Najos-Valencia et al). 2002;144:516-23

#### Echocardiography, stress

Assessment of residual myocardial viability in regions with chronic electrocardiographic Q-wave infarction (Schinkel et al). 2002;144:865-9

Determinants of tissue Doppler measures of regional diastolic function during dobutamine stress echocardiography (Najos-Valencia et al). 2002;144:516-23

The search for myocardial viability: do Q waves help? (Heidenreich). 2002;144:745-6 (Editorial)

#### Editorials

Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: identifying the guideposts for navigating the genetics landscape (Kraus and Hauser). 2002;144:747-9

Color me variable: the irreproducible nature of color flow Doppler in mitral and aortic regurgitation (Schiller). 2002;144:5-7

Demise of the routine electrophysiologic study for survivors of life-threatening ventricular arrhythmias (Curtis). 2002;144:380-2

Exercise testing for assessment of autonomic function (Lauer). 2002;144:580-2

Genetics in heart failure: practical incorporation of this new biological dimension (Donahue et al). 2002;144:938-40



In-stent restenosis: more fuel for the fire (Smyth et al). 2002;144:577-9

Quality of life in patients with life-threatening arrhythmias: does choice of therapy make a difference? (Exner). 2002;144:208-11

Reperfusion in waiting: what queue should we join? (Leung and Armstrong). 2002;144:377-9

Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients (Levinson and Ohman). 2002;144:750-2

The search for myocardial viability: do Q waves help? (Heidenreich). 2002;144:745-6

Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated? (Trichon and O'Connor). 2002;144:373-6

Selective L-type, T-type, and nonspecific calcium-channel blockers for stable angina pectoris (Thadani). 2002;144:8-10

The state of exercise training: a need for action (Whellan and O'Connor). 2002;144:1-4

Therapy for cardiovascular disease in patients with chronic kidney disease: appropriate caution or the absence of data (Reddan). 2002;144:206-7

Things ain't what they used to be: impact of a new definition of myocardial infarction (White). 2002;144:933-7

#### Electric countershock

Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter (Khan). 2002;144:11-22 (Curriculum cardiol.). Correction 2002;144:232

Transvenous internal cardioversion for atrial fibrillation: a randomized comparison between catheters with different coil length (Boriani et al). 2002;144:851-7

#### Electrocardiography

Assessment of residual myocardial viability in regions with chronic electrocardiographic Q-wave infarction (Schinkel et al). 2002;144:865-9

Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management (Anderson et al). 2002;144:769-81 (Meetings)

A combination of troponin T and 12-lead electrocardiography: a valuable tool for early prediction of long-term mortality in patients with chest pain without ST-segment elevation (Jernberg and Lindahl). 2002;144:804-10

Common electrocardiographic artifacts mimicking arrhythmias in ambulatory monitoring (Marquez et al). 2002;144:187-97 (Curriculum cardiol.)

Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration (Cooper et al). 2002;144:790-5

Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients (Levinson and Ohman). 2002;144:750-2 (Editorial)

The search for myocardial viability: do Q waves help? (Heidenreich). 2002;144:745-6 (Editorial)

Septal q waves as an indicator of risk of mortality in elderly patients with chronic heart failure (Shamim et al). 2002;144:740-4

Sex differences in QTc interval and QT dispersion: dynamics during exercise and recovery in healthy subjects (Chauhan et al). 2002;144:858-64

Significance of ST-segment morphology noted on electrocardiography during the recovery phase after exercise in patients with ischemic heart disease as analyzed with simultaneous dual-isotope single photon emission tomography (Akutsu et al). 2002;144:335-42

#### Electrophysiology

Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management (Anderson et al). 2002;144:769-81 (Meetings)

Demise of the routine electrophysiologic study for survivors of

life-threatening ventricular arrhythmias (Curtis). 2002;144:380-2 (Editorial)

Left ventricular electromechanical mapping: preliminary evidence of electromechanical changes after successful coronary intervention (Perin et al). 2002;144:693-701

Prognostic value of baseline electrophysiology studies in patients with sustained ventricular tachyarrhythmia: the Anti-arrhythmics Versus Implantable Defibrillators (AVID) trial (Brodsky et al). 2002;144:478-84

#### Enalapril

Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising (White et al). 2002;144:657-65

The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited (Parker et al). 2002;144:941-7 (Curriculum cardiol.)

#### Enoxaparin

Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study (Cohen et al). 2002;144:470-7

#### Epidemiologic factors

Angioplasty for coarctation in different aged patients (Walhout et al). 2002;144:180-6

Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study (Schmermund et al). 2002;144:212-18 (Trial design)

Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification (Mukherjee and Yadav). 2002;144:753-9 (Curriculum cardiol.)

Impact of sex and its interaction with age on the management of and outcome for patients with acute myocardial infarction in 4 Japanese hospitals (Matsui et al). 2002;144:101-7

Management of ventricular arrhythmias in diverse populations in California (Alexander et al). 2002;144:431-9

Perceptions of chest pain differ by race (Klingler et al). 2002;144:51-9

Race and sex differences in the refusal of cardiac catheterization among elderly patients hospitalized with acute myocardial infarction (Rathore et al). 2002;144:1052-6

Sex differences in QTc interval and QT dispersion: dynamics during exercise and recovery in healthy subjects (Chauhan et al). 2002;144:858-64

Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors (Čulić et al). 2002;144:1012-17

#### Eplerenone

Clinical implications of aldosterone blockade (Weber). 2002;144:S12-18

New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone (Funder). 2002;144:S8-11

New insights into the role of aldosterone in cardiorenal disease and the clinical implications—Introduction (Pitt). 2002;144:S1

#### Esmolol

Esmolol in acute ischemic syndromes (Mitchell et al). 2002;144:e9

#### European Society of Cardiology

Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations (Newby et al). 2002;144:957-80 (Meetings)

A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the Normative Aging Study (Orford et al). 2002;144:95-100

European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction:

how to use existing assays clinically and for clinical trials (Apple et al). 2002;144:981-6 (Meetings)  
Things ain't what they used to be: impact of a new definition of myocardial infarction (White). 2002;144:933-7 (Editorial)

#### Exercise test

Development and validation of a simple exercise test score for use in women with symptoms of suspected coronary artery disease (Morise et al). 2002;144:818-25  
Exercise testing for assessment of autonomic function (Lauer). 2002;144:580-2 (Editorial)  
Heart rate recovery after exercise is related to the insulin resistance syndrome and heart rate variability in elderly men (Lind and Andr  n). 2002;144:666-72  
Sex differences in QTc interval and QT dispersion: dynamics during exercise and recovery in healthy subjects (Chauhan et al). 2002;144:858-64  
Significance of ST-segment morphology noted on electrocardiography during the recovery phase after exercise in patients with ischemic heart disease as analyzed with simultaneous dual-isotope single photon emission tomography (Akutsu et al). 2002;144:335-42

#### Exercise therapy

Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT) (McKelvie et al). 2002;144:23-30  
Effects of exercise training on left ventricular volumes and function in patients with nonischemic cardiomyopathy: application of magnetic resonance myocardial tagging (Myers et al). 2002;144:719-25  
The state of exercise training: a need for action (Whellan and O'Connor). 2002;144:1-4 (Editorial)

#### Exercise tolerance

Cardiac troponin I: a potential marker of exercise intolerance in patients with moderate heart failure (Schulz and Kromer). 2002;144:351-8  
Characterization of the warm-up phenomenon in patients with coronary artery disease (Tuomainen et al). 2002;144:870-6  
Effect of atrial flutter on exercise tolerance in patients with grown-up congenital heart (GUCH) (Li et al). 2002;144:173-9  
Polymorphisms of the  $\beta_1$ -adrenergic receptor predict exercise capacity in heart failure (Wagoner et al). 2002;144:840-6  
Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial (Lee et al). 2002;144:60-7

## F

#### Fenfluramine

Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies (Sachdev et al). 2002;144:1065-73

#### Fenofibrate; see Procetofen

#### Fibrinolytic therapy; see Thrombolytic therapy

#### Framingham Heart Study

A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the Normative Aging Study (Orford et al). 2002;144:95-100

#### Free wall rupture, post-infarction; see Heart rupture, post-infarction

## G

#### Genetics

Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: identifying the guideposts for navigating the genetics landscape (Kraus and Hauser). 2002;144:747-9 (Editorial)

Association of angiotensin-converting enzyme DD genotype with blood pressure sensitivity to weight loss (Kostis et al). 2002;144:625-9

Association of the human minK gene 38G allele with atrial fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation (Lai et al). 2002;144:485-90

Genetics in heart failure: practical incorporation of this new biologic dimension (Donahue et al). 2002;144:938-40 (Editorial)

A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias (Agema et al). 2002;144:760-8 (Progress cardi.)

A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation (Hershberger et al). 2002;144:1081-6

Polymorphisms of the  $\beta_1$ -adrenergic receptor predict exercise capacity in heart failure (Wagoner et al). 2002;144:840-6

#### Glycoprotein IIb/IIIa inhibitors; see Platelet aggregation inhibitors

#### Growth hormone; see Somatotropin

## H

#### HDL cholesterol; see Lipoproteins, HDL/LDL cholesterol

#### Health status

Health values before and after pacemaker implantation (Lopez-Jimenez et al). 2002;144:687-92

#### Heart defects, congenital

Angioplasty for coarctation in different aged patients (Walhout et al). 2002;144:180-6

Cardiac rhythm and symptomatic arrhythmia in right atrial isomerism (Cheung et al). 2002;144:159-64

Effect of atrial flutter on exercise tolerance in patients with grown-up congenital heart (GUCH) (Li et al). 2002;144:173-9

Effectiveness of percutaneous device occlusion for atrial septal defect in adult patients with pulmonary hypertension (de Lezo et al). 2002;144:877-80

#### Heart failure, congestive

Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: the Framingham Heart Study (Walsh et al). 2002;144:733-9

Assessment of diastolic function by cardiovascular magnetic resonance (Paelinck et al). 2002;144:198-205 (Progress cardi.)

The cardiac component of cardiac cachexia (Florea et al). 2002;144:45-50

Cardiac troponin I: a potential marker of exercise intolerance in patients with moderate heart failure (Schulz and Kromer). 2002;144:351-8

Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure (Ahmed et al). 2002;144:365-72

Diuretic resistance predicts mortality in patients with advanced heart failure (Neuberg et al). 2002;144:31-8

Noninvasive estimation of both systolic and diastolic pulmonary artery pressure from Doppler analysis of tricuspid regurgitant velocity spectrum in patients with chronic heart failure (Lanzarini et al). 2002;144:1087-94

Polymorphisms of the  $\beta_1$ -adrenergic receptor predict exercise capacity in heart failure (Wagoner et al). 2002;144:840-6

A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation (Wieczorek et al). 2002;144:834-9

Septal q waves as an indicator of risk of mortality in elderly patients with chronic heart failure (Shamim et al). 2002;144:740-4

### Heart failure, congestive, therapy

- Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure (de Milliano et al). 2002;144:e3
- Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study (Burger et al). 2002;144:1102-8
- Effect of thalidomide in patients with chronic heart failure (Gullestad et al). 2002;144:847-50
- Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT) (McKelvie et al). 2002;144:23-30
- Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy (Adamopoulos et al). 2002;144:359-64
- An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area (Galatius et al). 2002;144:e2
- The pediatric randomized carvedilol trial in children with chronic heart failure: rationale and design (Shaddy et al). 2002;144:383-9 (Trial design)
- Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial (AF-CHF Trial Investigators). 2002;144:597-607 (Trial design)
- The state of exercise training: a need for action (Whellan and O'Connor). 2002;144:1-4 (Editorial)
- Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan Study (RITZ-4) (O'Connor et al). 2002;144:583-8 (Trial design)

### Heart rate

- Heart rate recovery after exercise is related to the insulin resistance syndrome and heart rate variability in elderly men (Lind and Andr  n). 2002;144:666-72
- Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising (White et al). 2002;144:657-65

### Heart rupture, post-infarction

- Nature and progression of pericardial effusion in patients with a first myocardial infarction: relationship to age and free wall rupture (Figueroa et al). 2002;144:251-8

### Heart septum

- Effectiveness of percutaneous device occlusion for atrial septal defect in adult patients with pulmonary hypertension (de Lezo et al). 2002;144:877-80
- In search of left septal fascicular block (MacAlpin). 2002;144:948-56 (Progress cardiol.)

### Heart valves, see also specific valve

- Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies (Sachdev et al). 2002;144:1065-73
- Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction (Zannad et al). 2002;144:508-15

### Hematocrit

- Relationship between hematocrit, primary hemostasis, and cardiovascular disease in athletes (Lippi et al). 2002;144:e14 (Letter)

### Hemodynamics

- Arterial elastance and heart-arterial coupling in aortic regurgitation are determined by aortic leak severity (Segers et al). 2002;144:568-76 (Progress cardiol.)
- Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angio-

graphic and clinical outcomes in the RESTORE trial (Gibson et al). 2002;144:130-5

- Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy (Angeja et al). 2002;144:649-56

### Hemostasis; see Blood coagulation

#### Heparin

- Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience (Gilchrist et al). 2002;144:73-80
- Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus (Kereiakes et al). 2002;144:615-24
- Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B) (Mukherjee et al). 2002;144:995-1002
- Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study (Cohen et al). 2002;144:470-7

#### HIV

- Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors (Meng et al). 2002;144:642-8

#### Hospitals

- Effects of hospital volume on long-term outcomes after percutaneous transluminal coronary angioplasty after acute myocardial infarction (Doucet et al). 2002;144:144-50
- A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario (Austin et al). 2002;144:290-6
- Short-term outcomes after percutaneous coronary intervention: effects of stenting and institutional volume shifts (Watanabe et al). 2002;144:309-14
- Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995 (McDonald et al). 2002;144:413-21

#### Hydroxymethylglutaryl-CoA reductase inhibitors

- Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitors on serum C-reactive protein levels: possible implications (McMullan et al). 2002;144:e13 (Letter)
- Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia (Olsson et al). 2002;144:1044-51
- Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial (Brown et al). 2002;144:1036-43
- High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease (Gotto). 2002;144:S33-42
- Management of dyslipidemia in the high-risk patient (Stein). 2002;144:S43-50
- New options in lipid management—can we extend the benefits of current therapy?—Introduction (Gotto and Paoletti). 2002;144:S19-20
- Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (Istvan). 2002;144:S27-32
- What do the statins tell us? (LaRosa). 2002;144:S21-6

#### Hypercholesterolemia and hyperlipidemia

- Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia (Melenovsky et al). 2002;144:e6
- Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia (Olsson et al). 2002;144:1044-51
- Efficacy and safety of rosuvastatin compared with pravastatin

and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial (Brown et al). 2002;144:1036-43

High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease (Gotto). 2002;144:S33-42

Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS) (Matalaka et al). 2002;144:674-7

Management of dyslipidemia in the high-risk patient (Stein). 2002;144:S43-50

New options in lipid management—can we extend the benefits of current therapy?—Introduction (Gotto and Paoletti). 2002;144:S19-20

Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial (Allen et al). 2002;144:678-86

Relationship between vascular dysfunction in peripheral arteries and ischemic episodes during daily life in patients with ischemic heart disease and hypercholesterolemia (Sondergaard et al). 2002;144:108-14

Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (Istvan). 2002;144:S27-32

What do the statins tell us? (LaRosa). 2002;144:S21-6

## Hypertension

Association of angiotensin-converting enzyme DD genotype with blood pressure sensitivity to weight loss (Kostis et al). 2002;144:625-9

Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy (Olsen et al). 2002;144:530-7

Peripheral endothelium-dependent flow-mediated vasodilation is associated with left ventricular mass in older persons with hypertension (Sung et al). 2002;144:39-44

## Hypertension, malignant

Tackling malignant hypertension: not so desperate now (Feldman et al). 2002;144:e4 (Letter)

## Hypertension, pulmonary

Effectiveness of percutaneous device occlusion for atrial septal defect in adult patients with pulmonary hypertension (de Lezo et al). 2002;144:877-80

## Hypertension, therapy

Aldosterone: cardiovascular assault (Struthers). 2002;144:S2-7

Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study (Wachtell et al). 2002;144:1057-64

Clinical implications of aldosterone blockade (Weber). 2002;144:S12-18

New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone (Funder). 2002;144:S8-11

New insights into the role of aldosterone in cardiorenal disease and the clinical implications—Introduction (Pitt). 2002;144:S1

Oral antihypertensive trial design and analysis under the pediatric exclusivity provision (Pasquali et al). 2002;144:608-14 (Trial design)

Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising (White et al). 2002;144:657-65

Risks and benefits of early treatment of acute myocardial infarction with an angiotensin-converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI-3 database (Avanzini et al). 2002;144:1018-25

Simple, shared guidelines raise the quality of antihypertensive treatment in routine care (Avanzini et al). 2002;144:726-32

## I

### Infant

Autonomic alterations in cocaine-exposed infants (Mehta et al). 2002;144:1109-15

### Insulin resistance

Exercise testing for assessment of autonomic function (Lauer). 2002;144:580-2 (Editorial)

Heart rate recovery after exercise is related to the insulin resistance syndrome and heart rate variability in elderly men (Lind and Andrén). 2002;144:666-72

### 3-Iodobenzylguanidine

Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure (de Milliano et al). 2002;144:e3

Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis (Hongo et al). 2002;144:122-9

### Ischemic heart disease; see Myocardial ischemia

### Isomerism, right atrial; see Heart defects, congenital

## K

### Kidney failure, chronic

Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease (McCullough et al). 2002;144:226-32

Therapy for cardiovascular disease in patients with chronic kidney disease: appropriate caution or the absence of data (Reddan). 2002;144:206-7 (Editorial)

## L

### Letters to the Editor

Chelation therapy for coronary heart disease (Prabha et al) (Letter); (Ernst) (Reply). 2002;144:e10, e11

Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitors on serum C-reactive protein levels: possible implications (McMullan et al). 2002;144:e13

Prevalence of *Chlamydia pneumoniae* in nonrheumatic stenotic aortic valves (Radke et al). 2002;144:e12

Relationship between hematocrit, primary hemostasis, and cardiovascular disease in athletes (Lippi et al). 2002;144:e14

Tackling malignant hypertension: not so desperate now (Feldman et al). 2002;144:e4

### Lipid-lowering agents; see Hydroxymethylglutaryl-CoA reductase inhibitors

### Lipoproteins, HDL/LDL cholesterol. see also Hypercholesterolemia and hyperlipidemia

Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia (Melenovsky et al). 2002;144:e6

High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease (Gotto). 2002;144:S33-42

A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression (Kuvin et al). 2002;144:165-72

Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease (Koba et al). 2002;144:1026-35

### Long QT syndrome

Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management (Anderson et al). 2002;144:769-81 (Meetings)



## Losartan

- Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study (Wachtell et al). 2002;144:1057-64
- Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising (White et al). 2002;144:657-65

## M

### Magnetic resonance imaging

- Assessment of diastolic function by cardiovascular magnetic resonance (Paclincx et al). 2002;144:198-205 (Progress cardiol.)
- Effects of exercise training on left ventricular volumes and function in patients with nonischemic cardiomyopathy: application of magnetic resonance myocardial tagging (Myers et al). 2002;144:719-25
- Quantification of valvular aortic stenosis by magnetic resonance imaging (Friedrich et al). 2002;144:329-34

### Medicare

- Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995 (McDonald et al). 2002;144:413-21

### Metoprolol

- Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure (de Milliano et al). 2002;144:e3

### MIBG scintigraphy; see 3-Iodobenzylguanidine

### Microcirculation

- Blunted vasodilatory responses in the cutaneous microcirculation of cigarette smokers (Pellaton et al). 2002;144:269-74
- Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy (Angeja et al). 2002;144:649-56
- Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina (Colonna et al). 2002;144:796-803

### Mitral valve insufficiency

- Color me variable: the irreproducible nature of color flow Doppler in mitral and aortic regurgitation (Schiller). 2002;144:5-7 (Editorial)
- Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction (Koelling et al). 2002;144:524-9
- Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated? (Trichon and O'Connor). 2002;144:373-6 (Editorial)
- Testing the test: the reliability of echocardiography in the sequential assessment of valvular regurgitation (Gottdiener et al). 2002;144:115-21

### Mitral valve stenosis

- Comparison of percutaneous transmittal commissurotomy with Inoue balloon technique and metallic commissurotomy: immediate and short-term follow-up results of a randomized study (Bhat et al). 2002;144:1074-80

### Monteplase

- A new thrombolytic agent, monteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: initial results of the Combining Monteplase with Angioplasty (COMA) trial (Inoue et al). 2002;144:e5

### Mortality

- Amiodarone and mortality among elderly patients with acute

myocardial infarction with atrial fibrillation (Kilborn et al). 2002;144:1095-101

Diuretic resistance predicts mortality in patients with advanced heart failure (Neuberg et al). 2002;144:31-8

Effect of anemia on 1-year mortality in patients with acute myocardial infarction (Al Falluji et al). 2002;144:636-41

Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction (Walsh et al). 2002;144:1003-11

Impact of cardiac catheterization-percutaneous coronary intervention timing on in-hospital mortality (Goldstein et al). 2002;144:561-7 (Progress cardiol.)

Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death (Heidenreich et al). 2002;144:422-30

Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease (Every et al). 2002;144:390-6

Septal q waves as an indicator of risk of mortality in elderly patients with chronic heart failure (Shamim et al). 2002;144:740-4

### MRI; see Magnetic resonance imaging

### Multivariate analysis

The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited (Parker et al). 2002;144:941-7 (Curriculum cardiol.)

### Myocardial infarction. see also Myocardial ischemia

C-Reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction (Zairis et al). 2002;144:782-9

A combination of troponin T and 12-lead electrocardiography: a valuable tool for early prediction of long-term mortality in patients with chest pain without ST-segment elevation (Jernberg and Lindahl). 2002;144:804-10

Effect of anemia on 1-year mortality in patients with acute myocardial infarction (Al Falluji et al). 2002;144:636-41

Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction (Walsh et al). 2002;144:1003-11

In-hospital outcome of acute myocardial infarction in patients with prior coronary artery bypass surgery (Mathew et al). 2002;144:463-9

A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario (Austin et al). 2002;144:290-6

Nature and progression of pericardial effusion in patients with a first myocardial infarction: relationship to age and free wall rupture (Figueroa et al). 2002;144:251-8

Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial (Anderson et al). 2002;144:81-8

Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina (Colonna et al). 2002;144:796-803

Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial Infarction and Depression-Intervention Trial (MIND-IT) (van den Brink et al). 2002;144:219-25 (Trial design)

### Myocardial infarction, diagnosis

Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations (Newby et al). 2002;144:957-80 (Meetings)

European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials (Apple et al). 2002;144:981-6 (Meetings)

Things ain't what they used to be: impact of a new definition of myocardial infarction (White). 2002;144:933-7 (Editorial)

**Myocardial infarction, drug therapy**

- Abciximab therapy improves 1-month survival rate in unscheduled patients with acute myocardial infarction undergoing routine infarct artery stent implantation (Antoniucci et al). 2002;144:315-22
- Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation (Kilborn et al). 2002;144:1095-101
- Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease (McCullough et al). 2002;144:226-32
- Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): a population-based perspective (Jackson et al). 2002;144:259-68
- Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus (Kereiakes et al). 2002;144:615-24
- Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration (Cooper et al). 2002;144:790-5
- Risks and benefits of early treatment of acute myocardial infarction with an angiotensin-converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI-3 database (Avanzini et al). 2002;144:1018-25

**Myocardial infarction, epidemiology**

- Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study (Schmermund et al). 2002;144:212-18 (Trial design)
- Impact of sex and its interaction with age on the management of and outcome for patients with acute myocardial infarction in 4 Japanese hospitals (Matsui et al). 2002;144:101-7
- Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors (Čulić et al). 2002;144:1012-17

**Myocardial infarction, therapy**

- Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era (Goodman et al). 2002;144:243-50
- Effects of hospital volume on long-term outcomes after percutaneous transluminal coronary angioplasty after acute myocardial infarction (Doucet et al). 2002;144:144-50
- How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction (Lundergan et al). 2002;144:456-62
- A new thrombolytic agent,alteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: initial results of the COMBining Alteplase with Angioplasty (COMA) trial (Inoue et al). 2002;144:e5
- Prognosis after acute myocardial infarction continues to improve in the reperfusion era in the community of Göteborg (Herlitz et al). 2002;144:89-94
- Race and sex differences in the refusal of cardiac catheterization among elderly patients hospitalized with acute myocardial infarction (Rathore et al). 2002;144:1052-6
- Reperfusion in waiting: what queue should we join? (Leung and Armstrong). 2002;144:377-9 (Editorial)

**Myocardial ischemia**

- Characterization of the warm-up phenomenon in patients with coronary artery disease (Tuomainen et al). 2002;144:870-6
- Coronary vasospasm as a possible cause of elevated cardiac troponin I in patients with acute coronary syndrome and insignificant coronary artery disease (Wang et al). 2002;144:275-81
- Esmolol in acute ischemic syndromes (Mitchell et al). 2002;144:e9

- Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience (Gilchrist et al). 2002;144:73-80
- Increased myocardial ischemia after food is not explained by endothelial dysfunction (Edwards et al). 2002;144:e8
- Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B) (Mukherjee et al). 2002;144:995-1002
- Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study (Cohen et al). 2002;144:470-7
- Relationship between vascular dysfunction in peripheral arteries and ischemic episodes during daily life in patients with ischemic heart disease and hypercholesterolemia (Søndergaard et al). 2002;144:108-14
- Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients (Levinson and Ohman). 2002;144:750-2 (Editorial)
- Significance of ST-segment morphology noted on electrocardiography during the recovery phase after exercise in patients with ischemic heart disease as analyzed with simultaneous dual-isotope single photon emission tomography (Akutsu et al). 2002;144:335-42
- Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan Study (RITZ-4) (O'Connor et al). 2002;144:583-8 (Trial design)

**Myocardial revascularization**

- Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry (Holubkov et al). 2002;144:826-33
- Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial (Gibson et al). 2002;144:130-5
- Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100 (Madan et al). 2002;144:151-8
- Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention (Home et al). 2002;144:491-500
- Is direct coronary stenting the best strategy for long-term outcome? Results of the multicentric randomized benefit evaluation of direct coronary stenting (BET) study (Elbaz et al). 2002;144:e7
- Left ventricular electromechanical mapping: preliminary evidence of electromechanical changes after successful coronary intervention (Perin et al). 2002;144:693-701
- Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus (Kereiakes et al). 2002;144:615-24
- Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications (Hillegeass et al). 2002;144:501-7
- Short-term outcomes after percutaneous coronary intervention: effects of stenting and institutional volume shifts (Watanabe et al). 2002;144:309-14

**Myocardial stunning**

- Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter (Khan). 2002;144:11-22 (Curriculum cardiol). Correction 2002;144:232

**Myocardium**

- Assessment of residual myocardial viability in regions with chronic electrocardiographic Q-wave infarction (Schinkel et al). 2002;144:865-9
- Does chronic *Chlamydia pneumoniae* infection increase the risk of myocardial injury? Insights from patients with non-

ST-elevation acute coronary syndromes (Wong et al). 2002;144:987-94

The search for myocardial viability: do Q waves help? (Heidenreich). 2002;144:745-6 (Editorial)

## N

### Natriuretic peptide, brain

Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study (Burger et al). 2002;144:1102-8

A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation (Wieczorek et al). 2002;144:834-9

### Neurotransmitters

Effect of  $\beta_2$ -adrenergic receptor functioning and increased norepinephrine on the hypercoagulable state with mental stress (von Känel et al). 2002;144:68-72

Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy (Olsen et al). 2002;144:530-7

### Nitric-oxide synthase

A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression (Kuvin et al). 2002;144:165-72

## O

### Outcome assessment (health care)

Third Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. 2002;144:881-932 (Meetings)

Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995 (Hlatky et al). 2002;144:397-403

### Outpatient clinics, hospital

An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area (Galatius et al). 2002;144:e2

## P

### Pacemaker, artificial

Health values before and after pacemaker implantation (Lopez-Jimenez et al). 2002;144:687-92

### Pediatric patient; see Child; Infant

### Pericardial effusion

Nature and progression of pericardial effusion in patients with a first myocardial infarction: relationship to age and free wall rupture (Figueroa et al). 2002;144:251-8

### Peripheral vascular diseases

Relationship between vascular dysfunction in peripheral arteries and ischemic episodes during daily life in patients with ischemic heart disease and hypercholesterolemia (Sondergaard et al). 2002;144:108-14

### Platelet aggregation inhibitors

Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100 (Madan et al). 2002;144:151-8

Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B) (Mukherjee et al). 2002;144:995-1002

### Polymorphism (genetics); see Genetics

### Postprandial period

Increased myocardial ischemia after food is not explained by endothelial dysfunction (Edwards et al). 2002;144:e8

### Procetofen

Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia (Melenovsky et al). 2002;144:e6

### Protease inhibitors

Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors (Meng et al). 2002;144:642-8

### Proteoglycans

Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation (Glover et al). 2002;144:702-9

In-stent restenosis: more fuel for the fire (Smyth et al). 2002;144:577-9 (Editorial)

### PTCA; see Angioplasty, transluminal, percutaneous coronary

### Pulmonary artery

Noninvasive estimation of both systolic and diastolic pulmonary artery pressure from Doppler analysis of tricuspid regurgitant velocity spectrum in patients with chronic heart failure (Lanzarini et al). 2002;144:1087-94

### Pulmonary hypertension; see Hypertension, pulmonary

## Q

### QT interval; see Electrocardiography; Long QT syndrome

### Quality of health care

A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario (Austin et al). 2002;144:290-6

Third Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. 2002;144:881-932 (Meetings)

### Quality of life

Cardiologists' discussions about sexuality with patients with chronic coronary artery disease (Bedell et al). 2002;144:239-42

Health values before and after pacemaker implantation (Lopez-Jimenez et al). 2002;144:687-92

Life after a ventricular arrhythmia (Hsu et al). 2002;144:404-12

Quality of life in patients with life-threatening arrhythmias: does choice of therapy make a difference? (Exner). 2002;144:208-11 (Editorial)

Quality of life in the Canadian Implantable Defibrillator Study (CIDS) (Irvine et al). 2002;144:282-9

Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial Infarction and Depression Intervention Trial (MIND-IT) (van den Brink et al). 2002;144:219-25 (Trial design)

## R

### Racial factors; see Epidemiologic factors

### Receptors, adrenergic, beta

Effect of  $\beta_2$ -adrenergic receptor functioning and increased norepinephrine on the hypercoagulable state with mental stress (von Känel et al). 2002;144:68-72

Polymorphisms of the  $\beta_1$ -adrenergic receptor predict exercise capacity in heart failure (Wagoner et al). 2002;144:840-6

### Renal failure, chronic; see Kidney failure, chronic

### Restenosis, coronary; see Coronary restenosis

### Revascularization, myocardial; see Myocardial revascularization

### Risk assessment. see also Epidemiologic factors

A comparison of the Framingham and European Society of

- Cardiology coronary heart disease risk prediction models in the Normative Aging Study (Orford et al). 2002;144:95-100
- Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator (Owens et al). 2002;144:440-8
- Effectiveness of a multidisciplinary chest pain unit for the assessment of coronary syndromes and risk stratification in the Florence area (Conti et al). 2002;144:630-5
- Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients (Levinsky and Ohman). 2002;144:750-2 (Editorial)

**Rosuvastatin**

- Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia (Olsson et al). 2002;144:1044-51
- Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial (Brown et al). 2002;144:1036-43

**S****Sarpogrelate**

- Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris (Kinugawa et al). 2002;144:e1

**Scintigraphy, MIBG; see 3-Iodobenzylguanidine****Septum, heart; see Heart septum****Sex factors; see Epidemiologic factors****Sexuality**

- Cardiologists' discussions about sexuality with patients with chronic coronary artery disease (Bedell et al). 2002;144:239-42

**Sibutramine**

- Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction (Zannad et al). 2002;144:508-15

**Smoking**

- Blunted vasodilatory responses in the cutaneous microcirculation of cigarette smokers (Pellaton et al). 2002;144:269-74

**Somatotropin**

- Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy (Adamopoulos et al). 2002;144:359-64

**SPECT; see Tomography, emission-computed, single-photon****ST segment; see Electrocardiography****Statins; see Hydroxymethylglutaryl-CoA reductase inhibitors****Stents**

- Abciximab therapy improves 1-month survival rate in selected patients with acute myocardial infarction undergoing routine infarct artery stent implantation (Antoniucci et al). 2002;144:315-22
- Emergency endovascular interventions for ruptured thoracic and abdominal aortic aneurysms (Doss et al). 2002;144:544-8
- Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation (Glover et al). 2002;144:702-9
- In-stent restenosis: more fuel for the fire (Smyth et al). 2002;144:577-9 (Editorial)
- Is direct coronary stenting the best strategy for long-term outcome? Results of the multicentric randomized benefit evaluation of direct coronary stenting (BET) study (Elbaz et al). 2002;144:e7
- Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis (Kamishirado et al). 2002;144:303-8

- Short-term outcomes after percutaneous coronary intervention: effects of stenting and institutional volume shifts (Watanabe et al). 2002;144:309-14

**Stress**

- Effect of  $\beta_2$ -adrenergic receptor functioning and increased nor-epinephrine on the hypercoagulable state with mental stress (von Känel et al). 2002;144:68-72

**Stress test; see Echocardiography, stress; Exercise test****Stroke; see Cerebrovascular accident****Sudden cardiac death; see Mortality****Sympathetic nervous system; see Autonomic nervous system****T****Tezosentan**

- Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan Study (RITZ-4) (O'Connor et al). 2002;144:583-8 (Trial design)

**Thalidomide**

- Effect of thalidomide in patients with chronic heart failure (Gullestad et al). 2002;144:847-50

**Thrombolytic therapy**

- C-Reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction (Zairis et al). 2002;144:782-9

- Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era (Goodman et al). 2002;144:243-50

- How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction (Lundergan et al). 2002;144:456-62

- Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy (Angeja et al). 2002;144:649-56

- Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration (Cooper et al). 2002;144:790-5

- Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial (Anderson et al). 2002;144:81-8

**Ticlopidine**

- Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis (Kamishirado et al). 2002;144:303-8

**Time factors**

- How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction (Lundergan et al). 2002;144:456-62

- Impact of cardiac catheterization-percutaneous coronary intervention timing on in-hospital mortality (Goldstein et al). 2002;144:561-7 (Progress cardiol.)

- Reperfusion in waiting: what queue should we join? (Leung and Armstrong). 2002;144:377-9 (Editorial)

**Tirofiban**

- Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study (Cohen et al). 2002;144:470-7

**Tomography, emission-computed, single-photon**

- Significance of ST-segment morphology noted on electrocardiography during the recovery phase after exercise in patients



with ischemic heart disease as analyzed with simultaneous dual-isotope single photon emission tomography (Akutsu et al). 2002;144:335-42

#### **Treatment refusal**

Race and sex differences in the refusal of cardiac catheterization among elderly patients hospitalized with acute myocardial infarction (Rathore et al). 2002;144:1052-6

#### **Tricuspid valve insufficiency**

Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction (Koelling et al). 2002;144:524-9

Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated? (Trichon and O'Connor). 2002;144:373-6 (Editorial)

#### **Triglycerides**

High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease (Gotto). 2002;144:533-42

#### **Troponin**

Cardiac troponin I: a potential marker of exercise intolerance in patients with moderate heart failure (Schulz and Kromer). 2002;144:351-8

Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations (Newby et al). 2002;144:957-80 (Meetings)

A combination of troponin T and 12-lead electrocardiography: a valuable tool for early prediction of long-term mortality in patients with chest pain without ST-segment elevation (Jernberg and Lindahl). 2002;144:804-10

Coronary vasospasm as a possible cause of elevated cardiac troponin I in patients with acute coronary syndrome and insignificant coronary artery disease (Wang et al). 2002;144:275-81

European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials (Apple et al). 2002;144:981-6 (Meetings)

Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients (Levinson and Ohman). 2002;144:750-2 (Editorial)

Things ain't what they used to be: impact of a new definition of myocardial infarction (White). 2002;144:933-7 (Editorial)

## **U**

#### **Ultrasonography, interventional**

Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial (Tardif et al). 2002;144:589-96 (Trial design)

Impact of deep vessel wall injury and vessel stretching on subsequent arterial remodeling after balloon angioplasty: a serial intravascular ultrasound study (Okura et al). 2002;144:323-8

## **V**

#### **Vasodilation**

Blunted vasodilatory responses in the cutaneous microcirculation of cigarette smokers (Pellaton et al). 2002;144:269-74

A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression (Kuvini et al). 2002;144:165-72

Peripheral endothelium-dependent flow-mediated vasodilation is associated with left ventricular mass in older persons with hypertension (Sung et al). 2002;144:39-44

#### **Ventricular arrhythmias; see Arrhythmia**

#### **Ventricular dysfunction, left**

Impact of disease activity on left ventricular performance in patients with acromegaly (Bruch et al). 2002;144:538-43

Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction (Koelling et al). 2002;144:524-9

A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation (Wieczorek et al). 2002;144:834-9

The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited (Parker et al). 2002;144:941-7 (Curriculum cardiol.)

Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated? (Trichon and O'Connor). 2002;144:373-6 (Editorial)

#### **Ventricular function, left**

Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure (Ahmed et al). 2002;144:365-72

Echocardiography-derived variables predict outcome in patients with nonischemic dilated cardiomyopathy with or without a restrictive filling pattern (Faris et al). 2002;144:343-50

Effects of exercise training on left ventricular volumes and function in patients with nonischemic cardiomyopathy: application of magnetic resonance myocardial tagging (Myers et al). 2002;144:719-25

Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction (Zannad et al). 2002;144:508-15

Left ventricular electromechanical mapping: preliminary evidence of electromechanical changes after successful coronary intervention (Perin et al). 2002;144:693-701

Peripheral endothelium-dependent flow-mediated vasodilation is associated with left ventricular mass in older persons with hypertension (Sung et al). 2002;144:39-44

#### **Ventricular function, right**

Noninvasive estimation of both systolic and diastolic pulmonary artery pressure from Doppler analysis of tricuspid regurgitant velocity spectrum in patients with chronic heart failure (Lanzarini et al). 2002;144:1087-94

#### **Ventricular remodeling**

Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study (Wachtell et al). 2002;144:1057-64

Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy (Olsen et al). 2002;144:530-7

#### **Verapamil**

Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising (White et al). 2002;144:657-65

## **W**

#### **Warm-up phenomenon**

Characterization of the warm-up phenomenon in patients with coronary artery disease (Tuomainen et al). 2002;144:870-6

#### **Weight loss**

Association of angiotensin-converting enzyme DD genotype with blood pressure sensitivity to weight loss (Kostis et al). 2002;144:625-9

Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction (Zannad et al). 2002;144:508-15

**Women**

Coronary vascular dysfunction in premenopausal women with diabetes mellitus (Di Carli et al). 2002;144:711-18

Development and validation of a simple exercise test score for use in women with symptoms of suspected coronary artery disease (Morise et al). 2002;144:818-25

Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women (Cantor et al). 2002;144:297-302

